Document:

Exhibit 10.2

 

SUBSCRIPTION AGREEMENT

 

Enumeral Biomedical Holdings, Inc.

200 CambridgePark Drive, Suite 2000

Cambridge, MA 02140

 

This Subscription Agreement (this “Agreement”)
has been executed by the subscriber set forth on the signature page hereof (the “Subscriber”) in connection
with the private placement offering (the “Offering”) of a minimum of $500,000 (the “Minimum
Offering”) and a maximum of $3,000,000 (the “Maximum Offering”) of Units of securities
(the “Units”), plus up to an additional $600,000 of Units to cover over-subscriptions, issued by Enumeral
Biomedical Holdings, Inc., a Delaware corporation (the “Company”), at a purchase price of $1,000 per
Unit (the “Purchase Price”). Each Unit consists of (i) one 12% Senior Secured Convertible Promissory
Note in the face amount of $1,150, substantially in the form of Exhibit A hereto (the “Note”),
and (ii) one warrant, substantially in the form of Exhibit B hereto (the “Warrant”), representing
the right to purchase Eleven Thousand Five Hundred (11,500) shares of the Company’s common stock, par value $0.001 per share
(“Common Stock”), exercisable for a period of five (5) years from issuance at an exercise price of $0.10
per share. Each Note is convertible into shares of Common Stock (the “Conversion Shares”) at a conversion
price and on the other terms set forth in the Note. The repayment of the Note is secured by the intellectual property of the Company,
as set forth in the Security Agreement, substantially in the form of Exhibit C hereto.

 

The minimum subscription is $50,000 (50
Units). The Company may accept subscriptions for less than $50,000 in its sole discretion.

 

The Units being subscribed for pursuant
to this Agreement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”).
The Offering is being made on a reasonable best efforts basis to “accredited investors,” as defined in Regulation D
under the Securities Act in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities
Act and Rule 506 of Regulation D. The Subscriber acknowledges receipt of a copy of the Registration Rights Agreement, substantially
in the form of Exhibit D hereto (the “Registration Rights Agreement”).

 

Each closing of the Offering (a “Closing,”
and the date on which such Closing occurs hereinafter referred to as the “Closing Date”) shall take place
at such place as is mutually agreed to by the Company and the Placement Agents (as defined below)).

 

The initial Closing will not occur unless:

 

		a.	funds deposited in escrow as described in Section 2(b) below equal at least the Minimum Offering,
and corresponding documentation with respect to such amounts has been delivered by the Subscriber and other “Subscribers”
under Subscription Agreements of like tenor with this Agreement (collectively, the “Subscribers”) as
described in Section 2(a) below; and

 

		b.	the other conditions set forth in Sections 7 and 8 shall have been satisfied.

 

     

     

    

 

Thereafter, the Company may conduct one
or more additional Closings for the sale of the Units up to the Maximum Offering amount until the termination of the Offering.
Unless terminated earlier by the Company, the Offering shall continue until May 19, 2017, which date may be extended for up to
thirty (30) additional days, by the mutual agreement of the Company and the Placement Agents, without notice to any Subscriber,
past, current or prospective (such date as so extended the “Offering Termination Date”).

 

Any written disclosure schedules or other
written information documents delivered to the Subscriber prior to Subscriber’s execution of this Agreement, and any such
document delivered to the Subscriber after Subscriber’s execution of this Agreement and prior to the Closing of the Subscriber’s
subscription hereunder, are collectively referred to as the “Disclosure Materials.”

 

“Business Day”
means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.

 

1.    Subscription.
The undersigned Subscriber hereby subscribes to purchase the number of Units set forth on the Omnibus Signature Page attached
hereto, for the aggregate Purchase Price as set forth on such Omnibus Signature Page, subject to the terms and conditions of this
Agreement and on the basis of the representations, warranties, covenants and agreements contained herein.

 

2.    Subscription
Procedure. To complete a subscription for the Units, the Subscriber must fully comply with the subscription procedure provided
in this Section on or before the Closing Date for Subscriber’s Units.

 

		a.	Subscription Documents. On or before the Closing Date, the Subscriber shall review, complete
and execute the Omnibus Signature Page to this Agreement, the Investor Profile, Anti-Money Laundering Form and Accredited Investor
Certification, each attached hereto following the Omnibus Signature Page (collectively, the “Subscription Documents”),
and deliver the Subscription Documents to the Company at the address set forth under the caption “How to subscribe for
Units in the private offering of Enumeral Biomedical Holdings, Inc.” below. Executed documents may be delivered by the
Subscriber to the Placement Agent that introduced them to the Offering by facsimile or electronic mail (e-mail), if the Subscriber
delivers the original copies of the documents to such Placement Agent as soon thereafter as is practicable and such Placement Agent
shall, in turn, deliver the documents to the Company.

 

		b.	Purchase Price. Simultaneously with the delivery of the Subscription Documents to the Company
as provided herein, and in any event on or prior to the Closing Date, the Subscriber shall deliver to Delaware Trust Company, in
its capacity as escrow agent (the “Escrow Agent”), under an escrow agreement among the Company, the Placement
Agents (as defined below) and the Escrow Agent (the “Escrow Agreement”), the full Purchase Price by certified
or other bank check or by wire transfer of immediately available funds, pursuant to the instructions set forth under the caption
“How to subscribe for Units in the private offering of Enumeral Biomedical Holdings, Inc.” below. Such funds
will be held for the Subscriber’s benefit and will be returned promptly, without interest or offset, if this Subscription
Agreement is not accepted by the Company or the Offering is terminated pursuant to its terms by the Company prior to the Closing.

 

    	2 

     

    

 

		c.	Company Discretion. The Subscriber understands and agrees that the Company in its sole discretion
reserves the right to accept or reject this or any other subscription for Units, in whole or in part, notwithstanding prior receipt
by the Subscriber of notice of acceptance of this subscription. The Company shall have no obligation hereunder until the Company
shall execute and deliver to the Subscriber an executed copy of this Agreement. If this subscription is rejected in whole, or the
Offering is terminated, all funds received from the Subscriber will be returned without interest or offset, and this Agreement
shall thereafter be of no further force or effect. If this subscription is rejected in part, the funds for the rejected portion
of this subscription will be returned without interest or offset, and this Agreement will continue in full force and effect to
the extent this subscription was accepted.

 

3.    Placement
Agents. Katalyst Securities LLC (“Katalyst”) and GP Nurmenkari Inc. (“GPN”),
each a broker-dealer licensed with FINRA, have been engaged on an co-exclusive basis as placement agents (the “Placement
Agents”) for the Offering on a reasonable best efforts basis. The Placement Agents and their sub-agents will be paid
at each Closing from the proceeds in the Escrow Account, aggregate cash commissions equal to 10% of the gross Purchase Price paid
by Subscribers in the Offering and will receive warrants to purchase a number of shares of Common Stock equal to 10% of the number
of Conversion Shares initially issuable, based upon a conversion price of $0.10 per share, upon conversion of the Notes contained
in the Units sold to Subscribers in the Offering, with a term of five (5) years after the Closing in which they are issued, and
at an exercise price of $0.05 per share (the “Placement Agent Warrants”). Any sub-agent of the Placement
Agents that introduces investors to the Offering will be entitled to share in the cash fees and Placement Agent Warrants attributable
to those investors as described above, pursuant to the terms of executed sub-agent agreements). The Company will also pay certain
expenses of the Placement Agents, including legal fees.

 

4.    Representations
and Warranties of the Company. The Company hereby represents and warrants to the Subscriber, as of the date hereof and on each
Closing Date (unless otherwise specified), the following:

 

		a.	Organization and Qualification. The Company is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware, has all requisite power and authority to carry on its business as
now conducted, and is qualified and in good standing as a foreign corporation in each jurisdiction in which the nature of the business
conducted by the Company or the property owned or leased by the Company requires such qualification, except to the extent that
the failure to be so qualified or be in good standing would not have a Material Adverse Effect (as defined below). The Company’s
subsidiaries are duly incorporated or organized, validly existing and in good standing under the laws of their jurisdiction of
incorporation or organization and have all requisite power and authority to carry on their business as now conducted. Such subsidiaries
are duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have
a Material Adverse Effect on their respective business or properties.

 

    	3 

     

    

 

		b.	Authorization, Enforcement, Compliance with Other Instruments.
(i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement,
the Notes, the Warrants, the Registration Rights Agreement, the Security Agreement, the Escrow Agreement and each of the other
agreements and documents that are exhibits hereto or thereto or are contemplated hereby or thereby or necessary or desirable to
effect the transactions contemplated hereby or thereby (the “Transaction Documents”) and to issue the
Notes, the Warrants, the Placement Agent Warrants, the Conversion Shares and the shares of Common Stock issuable upon exercise
of the Warrants (the “Warrant Shares”) and the Placement Agent Warrants (the “Placement Agent
Warrant Shares”), in accordance with the terms hereof and thereof, (ii) the execution and delivery by the Company
of each of the Transaction Documents and the consummation by it of the transactions contemplated hereby and thereby, including,
without limitation, the issuance of the Notes, the Conversion Shares, the Warrants, the Warrant Shares, and the Placement Agent
Warrant Shares, have been, or will be at the time of execution of such Transaction Document, duly authorized by the Company’s
Board of Directors, and no further consent or authorization is, or will be at the time of execution of such Transaction Document,
required by the Company, its respective Board of Directors or its stockholders, (iii) each of the Transaction Documents will be
duly executed and delivered by the Company, (iv) the Transaction Documents when executed and delivered by the Company and each
other party thereto will constitute the valid and binding obligations of the Company enforceable against the Company in accordance
with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’
rights and remedies. 

 

		c.	Capitalization. The authorized capital stock of the Company
consists of 300,000,000 shares of Common Stock and 10,000,000 shares of preferred stock, par value of $0.001 per share (the “Preferred
Stock”). As of the commencement of the Offering, the Company has 128,409,788 shares of Common Stock and no shares of
Preferred Stock issued and outstanding. All of the outstanding shares of Common Stock of the stock of each of the Company’s
subsidiaries have been duly authorized, validly issued and are fully paid and nonassessable. Except as set forth in the reports,
schedules, forms, statements and other documents filed by the Company with the Securities and Exchange Commission (the “SEC”)
on or prior to the date hereof and on or prior to the applicable Closing Date (the “SEC Reports” or “SEC
Filings”), no shares of capital stock of the Company or any of its subsidiaries will be subject to preemptive rights
or any other similar rights or any liens or encumbrances suffered or permitted by the Company; (ii) except as set forth in the
SEC Reports there will be no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its subsidiaries,
or contracts, commitments, understandings or arrangements by which the Company or any of its subsidiaries is or may become bound
to issue additional shares of capital stock of the Company or any of its subsidiaries, (iii) there will be no outstanding debt
securities of the Company or any of its subsidiaries other than indebtedness as set forth in the SEC Reports, (iv) other than pursuant
to the Registration Rights Agreement or as set forth in the SEC Reports, there will be no agreements or arrangements under which
the Company or any of its subsidiaries is obligated to register the sale of any of their securities under the Securities Act, (v)
there will be no outstanding registration statements of the Company or any of its subsidiaries, and there will be no outstanding
comment letters from the SEC or any other regulatory agency; (vi) there will be no securities or instruments of the Company or
any of its subsidiaries containing anti-dilution or similar provisions, including the right to adjust the exercise, exchange or
reset price under such securities, that will be triggered by the issuance of the Units as described in this Agreement; and (vii)
except as provided in this Agreement, no co-sale right, right of first refusal or other similar right will exist with respect to
the Units (or will exist with respect to the Conversion Shares, the Warrant Shares or the Placement Agent Warrant Shares) or the
issuance and sale thereof. Upon request, the Company will make available to the Subscriber true and correct copies of the Company’s
Certificate of Incorporation, as amended and in effect on the date hereof (the “Certificate of Incorporation”),
and the Company’s By-laws, as amended and in effect on the date hereof (the “By-laws”), and the
terms of all securities exercisable for Common Stock and the material rights of the holders thereof in respect thereto other than
stock options issued to officers, directors, employees and consultants.

 

    	4 

     

    

 

		d.	Issuance of Securities. The Notes, the Warrants and the Placement Agent Warrants are duly
authorized and, upon issuance in accordance with the terms hereof, shall be duly issued, fully paid and nonassessable, and shall
be free from all taxes, liens and charges with respect to the issue thereof. If and when issued, upon conversion of the Notes and
upon exercise of the Warrants and Placement Agent Warrants, the Conversion Shares, Warrant Shares and Placement Agent Warrant Shares
will be duly issued, fully paid and nonassessable and will be free from all taxes, liens and charges with respect to the issuance
thereof.

 

		e.	No Conflicts. None of the execution and delivery of or performance by the Company under
each Transaction Document or the consummation of the transactions contemplated by the Transaction Documents conflicts with or violates,
or causes a default under (with our without the passage of time or the giving of notice), or will result in the creation or imposition
of, any lien, charge or other encumbrance upon any of the assets of the Company under any agreement, evidence of indebtedness,
joint venture, commitment or other instrument to which the Company is a party or by which the Company or its assets may be bound,
any statute, rule, law or governmental regulation applicable to the Company, or any term of the Company’s Certificate of
Incorporation as in effect on the date hereof or any Closing Date for the Offering or By-Laws as in effect on the date hereof or
any Closing Date for the Offering of the Company, or any license, permit, judgment, decree, order, statute, rule or regulation
applicable to the Company or any of its assets, except in the case of a conflict, violation, lien, charge or other encumbrance
(except with respect to the Company’s Certificate of Incorporation or By-Laws) which would not, or could not reasonably be
expected to, have a material adverse effect on the assets, business, condition (financial or otherwise), results of operations
or future prospects of the Company and its subsidiaries taken as a whole (a “Material Adverse Effect”).
No consent, approval, authorization or other order of, or registration, qualification or filing with, any regulatory body, administrative
agency, or other governmental body is required for the execution and delivery of the Transaction Documents and the valid issuance
or sale of the Units, the Notes, the Warrants, the Placement Agent Warrants, the Conversion Shares, the Warrant Shares, and the
Placement Agent Warrant Shares, other than such as have been made or obtained and that remain in full force and effect, and except
for the filing of a Form D or any filings required to be made under state or foreign securities laws, which shall be timely filed
by the Company. Except those which could not reasonably be expected to have a Material Adverse Effect, neither the Company nor
any subsidiary of the Company is in violation of any term of or in default under its Certificate of Incorporation or By-Laws. Except
those which could not reasonably be expected to have a Material Adverse Effect, or as otherwise set forth in the Company’s
SEC Filings, neither the Company nor any subsidiary of the Company is in violation of any term of or in default under any material
contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or regulation
applicable to the Company and any subsidiary of the Company. The business of the Company and each subsidiary of the Company is
not being conducted, and shall not be conducted in violation of any material law, ordinance, or regulation of any governmental
entity, except for any violation which could not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect.

 

    	5 

     

    

 

		f.	SEC Filings; Financial Statements. The Company has filed and has, within the past two years,
timely filed (subject to 12b-25 filings with respect to certain periodic filings) all reports, schedules, forms, statements and
other documents required to be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of
1934, as amended (the “Exchange Act”) (all of the foregoing and all other documents filed with the SEC
prior to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents incorporated
by reference therein, being hereinafter referred to herein as the “SEC Filings”). The SEC Filings are
available to the Subscribers via the SEC’s EDGAR system. As of their respective dates, the SEC Filings complied in all material
respects with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder, and none of
the SEC Filings, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. As of their respective dates, the audited financial statements of the Company included
in the Company’s SEC Filings for the two year period ended December 31, 2016, and any subsequent unaudited interim financial
statements included in the Company’s SEC Filings (collectively, the “Financial Statements”) present
fairly, in all material respects, the financial position of the Company as of the dates specified and the results of operations
for the periods covered thereby. Such financial statements and related notes were prepared in accordance with United States generally
accepted accounting principles applied on a consistent basis throughout the periods indicated, except that the unaudited financial
statements omit full notes, and except for normal year-end adjustments. As of the date hereof, there are no outstanding or unresolved
comments in comment letters received from the staff of the SEC with respect to any of the SEC Filings.

 

		g.	Absence of Litigation. Except as set forth in the Company’s SEC Filings, there is
no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory
organization or body now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any subsidiary
of the Company, wherein an unfavorable decision, ruling or finding would (i) adversely affect the validity or enforceability of,
or the authority or ability of the Company to perform its obligations under, this Agreement or any of the other Transaction Documents,
or (ii) have a Material Adverse Effect.

 

    	6 

     

    

 

		h.	Acknowledgment Regarding Subscriber’s Purchase of the Units The Company acknowledges
and agrees that each Subscriber is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction
Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that each Subscriber is not acting
as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the
transactions contemplated hereby and thereby and any advice given by such Subscriber or any of their respective representatives
or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental
to such Subscriber’s purchase of the Units, Notes, Warrants (and the Conversion Shares and Warrant Shares, if applicable).
The Company further represents to the Subscribers that the Company’s decision to enter into the Transaction Documents has
been based solely on the independent evaluation by the Company and its representatives.

 

		i.	No General Solicitation. Neither the Company, nor any of its affiliates, nor, to the knowledge
of the Company, any person acting on its or their behalf, has engaged in any form of general solicitation or general advertising
(within the meaning of Regulation D) in connection with the offer or sale of the Units.

 

		j.	No Integrated Offering. Neither the Company, nor any of its affiliates, nor, to the knowledge
of the Company, any person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would require registration of the Units, Notes or Warrants
under the Securities Act or cause this offering of Units to be integrated with prior offerings by the Company for purposes of the
Securities Act.

 

		k.	Employee Relations. The Company is not involved in any labor dispute nor, to the knowledge
of the Company, is any such dispute threatened. The Company is not party to any collective bargaining agreement. To the best of
the Company’s knowledge, the Company’s employees are not members of any union, and the Company’s relationship
with its employees is good.

 

    	7 

     

    

 

		l.	Intellectual Property Rights. The Company has ownership or license or legal right to use
all patents, patent applications, copyrights, trade secrets, know-how, sequence information, data, knowledge and information including
chemical manufacturing data, specifications, formulations, testing and development data and tools for the discovery and development
of products and technology, trademarks, trade names, customer lists, designs, manufacturing or other processes, computer software,
systems, data compilation, research results or other proprietary rights used in the business of the Company or its subsidiaries
(collectively “Intellectual Property”). All of such patents, patent applications, registered trademarks
and registered copyrights have been duly registered in, filed in or issued by the United States Patent and Trademark Office, the
United States Register of Copyrights or the corresponding offices of other jurisdictions and have been maintained and renewed in
accordance with all applicable provisions of law and administrative regulations in the United States and all such jurisdictions.
The Company believes it has taken all reasonable steps required in accordance with sound business practice and business judgment
to establish and preserve its and its subsidiaries’ ownership of all material Intellectual Property with respect to their
products and technology. To the knowledge of the Company, there is no infringement of the Intellectual Property by any third party.
To the knowledge of the Company, the present business, activities and products of the Company and its subsidiaries do not infringe
any intellectual property of any other person. There is no proceeding charging the Company or its subsidiaries with infringement
of any adversely held Intellectual Property and the Company is unaware of any facts which are reasonably likely to form a basis
for any such proceeding. There are no proceedings that have been instituted or pending or, to the knowledge of the Company, threatened,
which challenge the rights of the Company or its subsidiaries to the use of the Intellectual Property. The Intellectual Property
owned by the Company and its subsidiaries, and to the knowledge of the Company, the Intellectual Property licensed to the Company
and its subsidiaries, has not been adjudged invalid or unenforceable, in whole or in part. There is no pending or, to the knowledge
of the Company, threatened proceeding by others challenging the validity or scope of any such Intellectual Property, and the Company
is unaware of any facts which are reasonably likely to form a basis for any such claim. Each of the Company and its subsidiaries
has the right to use, free and clear of material claims or rights of other persons, all of its customer lists, designs, computer
software, systems, data compilations, and other information that are required for its products or its business as presently conducted.
Neither the Company nor its subsidiaries is making unauthorized use of any confidential information or trade secrets of any person.
The activities of any of the employees on behalf of the Company or of its subsidiaries do not violate any agreements or arrangements
between such employees and third parties that are related to confidential information or trade secrets of third parties or that
restrict any such employee’s engagement in business activity of any nature. Each former and current employee or consultant
of the Company or its subsidiaries is a party to a written contract with the Company or its subsidiaries that assigns to the Company
or its subsidiaries, or has received an employee handbook that requires an employee to assign, all rights to all inventions, improvements,
discoveries and information relating to the Company or its subsidiaries, except for any failure to so do as would not reasonably
be expected to result in a Material Adverse Effect. All licenses or other agreements under which (i) the Company or its subsidiaries
employs rights in Intellectual Property, or (ii) the Company or its subsidiaries has granted rights to others in Intellectual Property
owned or licensed by the Company or its subsidiaries are in full force and effect, and there is no default (and there exists no
condition which, with the passage of time or otherwise, would constitute a default by the Company or such subsidiary) by the Company
or its subsidiaries with respect thereto.

 

    	8 

     

    

 

		m.	Environmental Laws.

 

		(i)	The Company and each subsidiary of the Company has complied with all applicable Environmental Laws
(as defined below), except for violations of Environmental Laws that, individually or in the aggregate, have not had and would
not reasonably be expected to have a Material Adverse Effect. There is, to the knowledge of the Company, no pending or threatened
civil or criminal litigation, written notice of violation, formal administrative proceeding, or investigation, inquiry or information
request, relating to any Environmental Law involving the Company or any subsidiary of the Company, except for litigation, notices
of violations, formal administrative proceedings or investigations, inquiries or information requests that, individually or in
the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement,
“Environmental Law” means any national, state, provincial or local law, statute, rule or regulation or
the common law relating to the environment or occupational health and safety, including without limitation any statute, regulation,
administrative decision or order pertaining to (i) treatment, storage, disposal, generation and transportation of industrial, toxic
or hazardous materials or substances or solid or hazardous waste; (ii) air, water and noise pollution; (iii) groundwater and soil
contamination; (iv) the release or threatened release into the environment of industrial, toxic or hazardous materials or substances,
or solid or hazardous waste, including without limitation emissions, discharges, injections, spills, escapes or dumping of pollutants,
contaminants or chemicals; (v) the protection of wild life, marine life and wetlands, including without limitation all endangered
and threatened species; (vi) storage tanks, vessels, containers, abandoned or discarded barrels, and other closed receptacles;
(vii) health and safety of employees and other persons; and (viii) manufacturing, processing, using, distributing, treating, storing,
disposing, transporting or handling of materials regulated under any law as pollutants, contaminants, toxic or hazardous materials
or substances or oil or petroleum products or solid or hazardous waste. As used above, the terms “release”
and “environment” shall have the meaning set forth in the Comprehensive Environmental Response, Compensation
and Liability Act of 1980, as amended.

 

		(ii)	To the knowledge of the Company there is no material environmental liability with respect to any
solid or hazardous waste transporter or treatment, storage or disposal facility that has been used by the Company or any subsidiary
of the Company.

 

		(iii)	The Company and each subsidiary of the Company (i) has received all permits, licenses or other
approvals required of it under applicable Environmental Laws to conduct its businesses and (ii) is in compliance, in all material
respects, with all terms and conditions of any such permit, license or approval.

 

		n.	Title. Except as set forth in the SEC Reports, the Company and each subsidiary of the Company
has good and marketable title to all of its personal property and assets free and clear of any material restriction, mortgage,
deed of trust, pledge, lien, security interest or other charge, claim or encumbrance which would have a Material Adverse Effect.
With respect to properties and assets it leases, except as set forth in the SEC Reports, the Company and each subsidiary of the
Company is in material compliance with such leases and holds a valid leasehold interest free of any liens, claims or encumbrances
which would have a Material Adverse Effect.

 

    	9 

     

    

 

		o.	Internal Accounting Controls. Except as set forth in the Company’s SEC Filings, the
Company is in material compliance with the provisions of the Sarbanes-Oxley Act of 2002 currently applicable to the Company. Except
as set forth in the Company’s SEC Filings, the Company maintains a system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles and to maintain asset accountability, and (iii) the recorded amounts for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with respect to any differences.

 

		p.	No Material Adverse Breaches, etc. Neither the Company nor any subsidiary of the Company
is subject to any charter, corporate or other legal restriction, or any judgment, decree, order, rule or regulation which in the
judgment of the Company’s officers has or is expected in the future to have a Material Adverse Effect. Except as set forth
in the Company’s SEC Filings, neither the Company nor any subsidiary of the Company is in breach of any contract or agreement
which breach, in the judgment of the Company’s officers, has or is expected to have a Material Adverse Effect.

 

		q.	Tax Status. The Company and each subsidiary of the Company has made and filed all U.S. federal
and state, income and all other material tax returns, reports and declarations required by any jurisdiction to which it is subject
and (unless and only to the extent that the Company or such subsidiary has set aside on its books provisions reasonably adequate
for the payment of all unpaid and unreported taxes) has paid all taxes and other governmental assessments and charges that are
material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good
faith and has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods
to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due from the
Company or any subsidiary of the Company by the taxing authority of any jurisdiction, and the officers of the Company know of no
basis for any such claim.

 

		r.	Certain Transactions. Except for arm’s length transactions pursuant to which the Company
and subsidiaries of the Company make payments in the ordinary course of business upon terms no less favorable than it could obtain
from third parties, none of the officers, directors, or employees of the Company or any subsidiary of the Company is presently
a party to any transaction with the Company or any subsidiary of the Company (other than for services as employees, officers and
directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing
for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee
or, to the knowledge of the Company, any corporation, partnership, trust or other entity in which any officer, director, or any
such employee has a substantial interest or is an officer, director, trustee or partner.

 

    	10 

     

    

 

		s.	Rights of First Refusal. The Company is not obligated to offer the securities offered hereunder
on a right of first refusal basis or otherwise to any third parties including, but not limited to, current or former stockholders
of the Company, underwriters, brokers, agents or other third parties.

 

		t.	Reliance. The Company acknowledges that the Subscribers are relying on the representations
and warranties made by the Company hereunder and that such representations and warranties are a material inducement to the Subscriber
purchasing the Units. The Company further acknowledges that without such representations and warranties of the Company made hereunder,
the Subscribers would not enter into this Agreement.

 

		u.	Brokers’ Fees. The Company does not have any liability or obligation to pay any fees
or commissions to any Broker, finder or agent with respect to the transactions contemplated by this Agreement, except for (a) the
payment of the Placement Agent Fees to the Placement Agents, as applicable, (b) payments to Katalyst and to persons affiliated
with or formerly affiliated with Katalyst pursuant to the terms of that certain Placement Agent Agreement dated as of June 21,
2016 (as such term is defined therein), and (c) payments to Katalyst and to persons affiliated with or formerly affiliated with
Katalyst pursuant to the terms of that certain Warrant Agent Agreement, dated as of October 26, 2016 (as such term is defined therein);
provided, however, that Katalyst and other brokers or agents participating in the Offering shall only be entitled to a fee with
respect to the Offering pursuant to clause (a) of this paragraph, and in no event entitled to multiple fees in combination thereof.

 

		v.	Insurance. The Company has insurance policies of the type and in amounts customarily carried
by organizations conducting businesses or owning assets similar to those of the Company and its subsidiaries. There is no material
claim pending under any such policy as to which coverage has been questioned, denied or disputed by the underwriter of such policy.

 

		w.	Material Changes. Since the respective date of the latest consolidated balance sheet of
the Company included in the financial statements contained within the SEC Reports, except as specifically disclosed in the Company’s
SEC Filings, (i) there have been no events, occurrences or developments that have had or would reasonably be expected to have a
Material Adverse Effect with respect to the Company, (ii) the Company has not incurred any material liabilities (contingent or
otherwise) other than (A) trade payables, accrued expenses and other liabilities incurred in the ordinary course of business consistent
with past practice and (B) liabilities not required to be reflected in the financial statements of the Company pursuant to GAAP
or to be disclosed in filings made with the SEC, (iii) the Company has not materially altered its method of accounting or the manner
in which it keeps its accounting books and records, (iv) the Company has not declared or made any dividend or distribution of cash
or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock, (v) the Company has not issued any equity securities to any officer, director or affiliate, except Common Stock issued in
the ordinary course pursuant to existing Company stock option or stock purchase plans or executive and director corporate arrangements
disclosed in the Company’s SEC Filings, (vi) there has not been any change or amendment to, or any waiver of any material
right under, any material contract under which the Company, or any of their assets are bound or subject, and (vii) except for the
issuance of the Units contemplated by this Agreement, no event, liability or development has occurred or exists with respect to
the Company nor its businesses, properties, operations or financial condition, as applicable, that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made that has not been publicly disclosed in
the Company’s SEC Filings.

 

    	11 

     

    

 

		x.	Transactions With Affiliates and Employees. None of the officers or directors of the Company
and, to the Company’s knowledge, none of the employees of the Company, is a party to any transaction with the Company or
to a transaction contemplated by the Company (other than for services as employees, officers and directors) that would be required
to be disclosed by the Company pursuant to Item 404 of Regulation S-K promulgated under the Securities Act, except as contemplated
by the Transaction Documents or set forth in the Company’s SEC Filings.

 

		y.	Off-Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship
between the Company and an unconsolidated or other off-balance sheet entity that is required to be disclosed by the Company in
its SEC Filings (including, for purposes hereof, any that are required to be disclosed in a Form 10) and is not so disclosed or
that otherwise would have a Material Adverse Effect.

 

		z.	Disclosure Materials. The Company’s SEC Filings taken as a whole do not contain an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading.

 

		aa.	Investment Company. The Company is not required to be registered as, and is not an affiliate
of, and immediately following the Closing will not be required to register as, an “investment company” within the meaning
of the Investment Company Act of 1940, as amended.

 

5.    Representations,
Warranties and Agreements of the Subscriber. The Subscriber represents and warrants to, and agrees with, the Company the following:

 

		a.	Investment Purpose. Each Subscriber is acquiring the Units, Notes, and, if applicable, the
Conversion Shares and Warrant Shares (the Units, Notes, Warrants, Conversion Shares and Warrant Shares being hereinafter referred
to collectively as the “Securities”), for its own account for investment only and not with a view towards,
or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under
the Securities Act; provided, however, that by making the representations herein, such Subscriber reserves the right to dispose
of the Securities at any time in accordance with or pursuant to an effective registration statement covering such Securities, or
an available exemption under the Securities Act. Each Subscriber agrees not to sell, hypothecate or otherwise transfer the Securities
unless such Securities are registered under the federal and applicable state securities laws or unless, in the opinion of counsel
satisfactory to the Company, an exemption from such law is available.

 

    	12 

     

    

 

		b.	Residence of Subscriber. Each Subscriber resides in the jurisdiction set forth on the Subscriber
Omnibus Signature Page affixed hereto.

 

		c.	Accredited Investor Status. The Subscriber meets the requirements of at least one of the
suitability standards for an “Accredited Investor” as that term is defined in Rule 501(a) of Regulation D, for the
reason set forth on the Investor Certification attached hereto as Annex B.

 

		d.	Intentionally omitted. 

 

		e.	Accredited Investor Qualifications. A Subscriber (i) if a natural person, represents that
such Subscriber has reached the age of 21 and has full power and authority to execute and deliver this Agreement and all other
related agreements or certificates and to carry out the provisions hereof and thereof; (ii) if a corporation, partnership, or limited
liability company or partnership, or association, joint stock company, trust, unincorporated organization or other entity, represents
that such entity was not formed for the specific purpose of acquiring the Units, such entity is duly organized, validly existing
and in good standing under the laws of the state of its organization, the consummation of the transactions contemplated hereby
is authorized by, and will not result in a violation of state law or its charter or other organizational documents, such entity
has full power and authority to execute and deliver this Agreement and all other related agreements or certificates and to carry
out the provisions hereof and thereof and to purchase and hold the Units and underlying securities, the execution and delivery
of this Agreement has been duly authorized by all necessary action, this Agreement has been duly executed and delivered on behalf
of such entity and is a legal, valid and binding obligation of such entity; or (iii) if executing this Agreement in a representative
or fiduciary capacity, represents that it has full power and authority to execute and deliver this Agreement in such capacity and
on behalf of the subscribing individual, ward, partnership, trust, estate, corporation, or limited liability company or partnership,
or other entity for whom such Subscriber is executing this Agreement, and such individual, partnership, ward, trust, estate, corporation,
or limited liability company or partnership, or other entity has full right and power to perform pursuant to this Agreement and
make an investment in the Company, and represents that this Agreement constitutes a legal, valid and binding obligation of such
entity. The execution and delivery of this Agreement will not violate or be in conflict with any order, judgment, injunction, agreement
or controlling document to which such Subscriber is a party or by which it is bound.

 

		f.	Subscriber Relationship with Brokers. The Subscriber’s substantive relationship with
a broker, if any, for the transactions contemplated hereby, or subagent thereof (collectively, “Brokers”), through
which a Subscriber may be subscribing for the Units predates such Broker’s contact with the Subscriber regarding an investment
in the Units.

 

		g.	Solicitation. The Subscriber is unaware of, is in no way relying on, and did not become
aware of the offering of the Units through or as a result of, any form of general solicitation or general advertising including,
without limitation, any article, notice, advertisement or other communication published in any newspaper, magazine or similar media
or broadcast over television or radio, in connection with the offering and sale of the Units and is not subscribing for the Units
and did not become aware of the offering of the Units through or as a result of any seminar or meeting to which the Subscriber
was invited by, or any solicitation of a subscription by, a person not previously known to the Subscriber in connection with investments
in securities generally.

 

    	13 

     

    

 

		h.	Brokerage Fees. Except as otherwise provided herein, the Subscriber has taken no action
that would give rise to any claim by any person for brokerage commissions, finders’ fees or the like relating to this Agreement
or the transaction contemplated hereby.

 

		i.	Subscriber’s Advisors. The Subscriber and the Subscriber’s attorney, accountant,
purchaser representative and/or tax advisor, if any (collectively, the “Advisors”), as the case may be,
has such knowledge and experience in financial, tax, and business matters, and, in particular, investments in securities, so as
to enable it to utilize the information made available to it in connection with the Units to evaluate the merits and risks of an
investment in the Units and the Company and to make an informed investment decision with respect thereto.

 

		j.	Subscriber Liquidity. Each Subscriber has adequate means of providing for such Subscriber’s
current financial needs and foreseeable contingencies and has no need for liquidity of its investment in the Units for an indefinite
period of time, and after purchasing the Units, the Subscriber will be able to provide for any foreseeable current needs and possible
personal contingencies. The Subscriber must bear and acknowledges the substantial economic risks of the investment in the Units
including the risk of illiquidity and the risk of a complete loss of this investment.

 

		k.	High Risk Investment. The Subscriber is aware that an investment in the Units involves a
number of very significant risks and has carefully researched and reviewed and understands the risks of, and other considerations
relating to, the purchase of the Units, including but not limited to the Company’s disclosure that the Company believes that
it only has sufficient liquidity to fund operations into May 2017, and that, even with receipt of funds from this Offering, the
Company will require additional capital, without which the Company will be required to downsize or wind down its operations through
liquidation, bankruptcy, or a sale of its assets. Subscriber acknowledges that, among other things, while the Company and its
subsidiaries shall have entered into the Security Agreement with the Subscriber and the Collateral Agent, pursuant to which the
Company and its subsidiaries shall have granted and conveyed to the Collateral Agent, for the benefit of the Subscriber, a security
interest in intellectual property of the Company and its subsidiaries, at all times that the Subscriber’s Note remains outstanding,
which shall be governed by the laws of the State of New York, neither the Company nor the Collateral Agent has and neither of them
intends to take any action to perfect any security interest in any intellectual property of the Company and its subsidiaries in
any jurisdiction outside of the United States of America.

 

		l.	Reliance on Exemptions. Each Subscriber understands that the Units are being offered and
sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities
laws and that the Company is relying in part upon the truth and accuracy of, and such Subscriber’s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of such Subscriber set forth herein in order to determine the availability
of such exemptions and the eligibility of such Subscriber to acquire the Units.

 

    	14 

     

    

 

		m.	Information. Each Subscriber and its Advisors have been furnished with all documents and
materials relating to the business, finances and operations of the Company and its subsidiaries and information that such Subscriber
requested and deemed material to making an informed investment decision regarding such Subscriber’s purchase of the Units
and the underlying securities. Each Subscriber and its Advisors have been afforded the opportunity to review such documents and
materials, as well as the Company’s SEC Filings, as such term is defined below (hard copies of which were made available
to the Subscriber upon request to the Company or were otherwise accessible to the Subscriber via the SEC’s EDGAR system),
and the information contained therein. Each Subscriber and its Advisors have been afforded the opportunity to ask questions of
the Company and its management. Each Subscriber understands that such discussions, as well as any written information provided
by the Company, were intended to describe the aspects of the Company’s business and prospects which the Company believes
to be material, but were not necessarily a thorough or exhaustive description, and except as expressly set forth in this Agreement,
the Company makes no representation or warranty with respect to the completeness of such information and makes no representation
or warranty of any kind with respect to any information provided by any entity other than the Company. Some of such information
may include projections as to the future performance of the Company and its subsidiaries, which projections may not be realized,
may be based on assumptions which may not be correct and may be subject to numerous factors beyond the Company’s and its
subsidiaries’ control. Additionally, each Subscriber understands and represents that such Subscriber is purchasing the Units
notwithstanding the fact that the Company and its subsidiaries may disclose in the future certain material information the Subscriber
has not received, including the financial results of the Company and its subsidiaries for their current fiscal quarters. Neither
such inquiries, nor any other due diligence investigations conducted by such Subscriber or its Advisors, shall modify, amend or
affect such Subscriber’s right to rely on the Company’s representations and warranties contained in Section 4 above.
Each Subscriber has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment
decision with respect to its acquisition of the Units.

 

		n.	No Other Representations or Information. In evaluating the suitability of an investment
in the Units, the Subscriber has not relied upon any representation or information (oral or written) with respect to the Company
or its subsidiaries, or otherwise, other than as stated in this Agreement, the Note, the Warrants, the Registration Rights Agreement,
and the Security Agreement. No other oral or written representations have been made, or oral or written information furnished,
to the Subscriber or its Advisors, if any, in connection with the offering of the Units.

 

		o.	No Governmental Review. Each Subscriber understands that no United States federal or state
agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Units, or
the fairness or suitability of the Units, nor have such authorities passed upon or endorsed the merits of the offering of the Units.

 

    	15 

     

    

 

		p.	Transfer or Resale. Each Subscriber understands that: (i) the Units and the underlying securities
have not been and may not be registered under the Securities Act or any state securities laws, and may not be offered for sale,
sold, assigned or transferred unless (A) subsequently registered thereunder, or (B) such Subscriber shall have delivered to the
Company an opinion of counsel, in a generally acceptable form, to the effect that such securities to be sold, assigned or transferred
may be sold, assigned or transferred pursuant to an exemption from such registration requirements; (ii) any sale of such securities
made in reliance on Rule 144 under the Securities Act (or a successor rule thereto) (“Rule 144”) may be made only in
accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of such securities under circumstances
in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in
the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the
SEC thereunder; and (iii) the Company is not, and except as otherwise set forth in this Agreement, no other person is, under any
obligation to register such securities under the Securities Act or any state securities laws or to comply with the terms and conditions
of any exemption thereunder. The Company reserves the right to place stop transfer instructions against the shares and certificates
for the Conversion Shares and Warrant Shares to the extent specifically set forth under this Agreement. There can be no assurance
that there will be any market or resale for the Conversion Shares and Warrant Shares, nor can there be any assurance that the Conversion
Shares and Warrant Shares will be freely transferable at any time in the foreseeable future.

 

		q.	Legends. Each Subscriber understands that the certificates or other instruments representing
the Notes, Warrants, Conversion Shares and Warrant Shares shall bear a restrictive legend in substantially the following form (and
a stop transfer order may be placed against transfer of such stock certificates):

 

THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”).
THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) OUTSIDE THE UNITED STATES
IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, (C) IN COMPLIANCE WITH RULE 144 OR 144A THEREUNDER, IF AVAILABLE,
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, (D) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT, OR (E) IN A TRANSACTION
THAT DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS, AND THE HOLDER HAS, PRIOR
TO SUCH SALE, FURNISHED TO THE COMPANY AN OPINION OF COUNSEL OR OTHER EVIDENCE OF EXEMPTION, IN EITHER CASE REASONABLY SATISFACTORY
TO THE COMPANY. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

 

    	16 

     

    

 

The Company
shall use its commercially reasonable efforts to cause its Transfer Agent to remove the legend set forth above from the Conversion
Shares or Warrant Shares, as applicable, and, within three (3) business days, shall issue a certificate without such legend to
the holder of such Conversion Shares or Warrant Shares, as applicable, upon which it is stamped, if, unless otherwise required
by state securities laws, (i) the Subscriber or its broker make the necessary representations and warranties to the transfer agent
for the Common Stock that it has complied with the prospectus delivery requirements in connection with a sale transaction, provided
the Conversion Shares or Warrant Shares, as applicable, are registered under the Securities Act or (ii) in connection with an actual
sale transaction, after such holder provides the Company with an opinion of counsel satisfactory to the Company, which opinion
shall be in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public
sale, assignment or transfer of the Conversion Shares or Warrant Shares, as applicable, may be made without registration under
the Securities Act.

 

		r.	Authorization, Enforcement. The Subscriber has the requisite power and authority to enter
into and perform under this Agreement and the other Transaction Documents, and to purchase the Units and underlying securities
being sold to it hereunder. The execution, delivery and performance of this Agreement and the Transaction Documents by such Subscriber
and the consummation by Subscriber of the transactions contemplated hereby and thereby have been duly authorized by all necessary
corporate or partnership action, and no further consent or authorization of such Subscriber or Subscriber’s Board of Directors,
stockholders, partners, members, as the case may be, is required. This Agreement and the other Transaction Documents (to the extent
the Subscriber is party thereto) have been duly authorized, executed and delivered by such Subscriber and upon execution of this
Agreement and the Transaction Documents by the other parties hereto and thereto, constitute, or shall constitute when executed
and delivered, a valid and binding obligation of such Subscriber enforceable against such Subscriber in accordance with the terms
hereof and thereof, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors’ rights and remedies.

 

		s.	No Conflicts. The execution, delivery and performance of this Agreement and the other Transaction
Documents and the consummation by such Subscriber of the transactions contemplated hereby and thereby or relating hereto do not
and will not (i) if the Subscriber is not an individual, result in a violation of such Subscriber’s charter documents or
bylaws or other organizational documents or (ii) conflict with, or constitute a default (or an event which with notice or lapse
of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of any agreement, indenture or instrument or obligation to which such Subscriber is a party or by which its properties or assets
are bound, or result in a violation of any law, rule, or regulation, or any order, judgment or decree of any court or governmental
agency applicable to such Subscriber or its properties (except for such conflicts, defaults and violations as would not, individually
or in the aggregate, have a material adverse effect on such Subscriber). Such Subscriber is not required to obtain any consent,
authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute,
deliver or perform any of its obligations under this Agreement and the other Transaction Documents or to purchase the Units in
accordance with the terms hereof, provided that for purposes of the representation made in this sentence, such Subscriber is assuming
and relying upon the accuracy of the relevant representations and agreements of the Company herein.

 

    	17 

     

    

 

		t.	Receipt of Documents. Each Subscriber, its counsel and/or its Advisors have received and
read in their entirety: (i) this Agreement and each representation, warranty and covenant set forth herein; and (ii) all due diligence
and other information necessary to verify the accuracy and completeness of such representations, warranties and covenants; each
Subscriber has received answers to all questions such Subscriber submitted to the Company regarding an investment in the Company;
and each Subscriber has relied on the information contained therein and has not been furnished any other documents, literature,
memorandum or prospectus.

 

		u.	Status as a Former Shell Company. Each Subscriber understands that the Company is a former
“shell company” as such term is defined in Rule 12b-2 under the Exchange Act. The Company ceased to be
a “shell company” on July 31, 2014, and filed Form 10 type information under cover of Form 8-K on August
6, 2014. Pursuant to Rule 144(i), securities issued by a current or former shell company (such as the Securities) that otherwise
meet the holding period and other requirements of Rule 144 nevertheless cannot be sold in reliance on Rule 144 until one year after
such company (a) is no longer a shell company; and (b) has filed current “Form 10 information” (as defined
in Rule 144(i)) with the SEC reflecting that it is no longer a shell company, and provided that at the time of a proposed sale
pursuant to Rule 144, such company is subject to the reporting requirements of section 13 or 15(d) of the Exchange Act and has
filed all reports and other materials required to be filed by section 13 or 15(d) of the Exchange Act, as applicable, during the
preceding 12 months (or for such shorter period that the issuer was required to file such reports and materials), other than Form
8-K reports. As a result, the restrictive legends on certificates for the securities cannot be removed except in connection with
an actual sale meeting the foregoing requirements or pursuant to resale under an effective registration statement.

 

		v.	Trading Activities. The Subscriber’s trading activities with respect to the Common
Stock shall be in compliance with all applicable federal and state securities laws, rules and regulations and the rules and regulations
of the principal market on which the Common Stock is listed or traded. Neither the Subscriber nor its affiliates has an open short
position in the Common Stock and, except as set forth below, the Subscriber shall not, and shall not cause any of its affiliates
under common control with the Subscriber, to engage in any short sale as defined in any applicable SEC or Financial Industry Regulatory
Authority (“FINRA”) rules or any hedging transactions with respect to the Common Stock until the earlier
to occur of (i) the first anniversary of the initial Closing Date and (ii) the Subscriber no longer owns Notes, Warrants, Conversion
Shares or Warrant Shares. Without limiting the foregoing, the Subscriber agrees not to engage in any naked short transactions in
excess of the amount of shares owned (or an offsetting long position) by the Subscriber.

 

    	18 

     

    

 

		w.	Regulation FD. Each Subscriber acknowledges and agrees that certain of the information received
by it in connection with the transactions contemplated by this Agreement is of a confidential nature and may be regarded as material
non-public information under Regulation FD promulgated by the SEC and that such information has been furnished to the Subscriber
for the sole purpose of enabling the Subscriber to consider and evaluate an investment in the Units. Each Subscriber further acknowledges
that prior to receiving such information, Subscriber executed a confidentiality agreement or similar agreement with the Company.
The Subscriber agrees that it will treat such information in a confidential manner, will not use such information for any purpose
other than evaluating an investment in the Units, will not, directly or indirectly, trade or permit the Subscriber’s agents,
representatives or affiliates to trade in any securities of the Company while in possession of material non-public information
and will not, directly or indirectly, disclose or permit the Subscriber’s agents, representatives or affiliates to disclose
any of such information without the Company’s prior written consent. The Subscriber shall make its agents, affiliates and
representatives aware of the confidential nature of the information contained herein and the terms of this section including the
Subscriber’s agreement to not disclose such information, to not trade in the Company’s securities while such information
remains material non-public information and to be responsible for any disclosure or other improper use of such information by such
agents, affiliates or representatives. Likewise, without the Company’s prior written consent, the Subscriber will not, directly
or indirectly, make any statements, public announcements or other release or provision of information in any form to any trade
publication, to the press or to any other person or entity whose primary business is or includes the publication or dissemination
of information related to the transactions contemplated by this Agreement.

 

		x.	No Legal Advice from the Company. Each Subscriber acknowledges that it had the opportunity
to review this Agreement and the transactions contemplated by this Agreement with its own legal counsel and investment and tax
Advisors. Each Subscriber is relying solely on such Advisors and not on any statements or representations of the Company or any
of its employees, representatives or agents for legal, tax, economic and related considerations or investment advice with respect
to this investment, the transactions contemplated by this Agreement or the securities laws of any jurisdiction.

 

		y.	No Group Participation. Each Subscriber and its affiliates is not a member of any group,
nor is any Subscriber acting in concert with any other person, including any other Subscriber, with respect to its acquisition
of the Units and underlying securities.

 

		z.	Reliance. Any information which the Subscriber has heretofore furnished or is furnishing
herewith to the Company or any Broker is complete and accurate and may be relied upon by the Company and any Broker in determining
the availability of an exemption from registration under U.S. federal and state securities laws in connection with the offering
of securities as described in this Agreement and the related summary term sheet and transmittal letter, if any. The Subscriber
further represents and warrants that it will notify and supply corrective information to the Company immediately upon the occurrence
of any change therein occurring prior to the Company’s issuance of the Units. Within five (5) days after receipt of a request
from the Company or any Broker, the Subscriber will provide such information and deliver such documents as may reasonably be necessary
to comply with any and all laws and ordinances to which the Company or any Broker is subject.

 

    	19 

     

    

 

		aa.	(For ERISA plan Subscribers only). The fiduciary of the ERISA plan represents that
such fiduciary has been informed of and understands the Company’s investment objectives, policies and strategies, and that
the decision to invest “plan assets” (as such term is defined in ERISA) in the Company is consistent
with the provisions of ERISA that require diversification of plan assets and impose other fiduciary responsibilities. The Subscriber
fiduciary or plan (a) is responsible for the decision to invest in the Company; (b) is independent of the Company or any of its
affiliates; (c) is qualified to make such investment decision; and (d) in making such decision, the Subscriber fiduciary or plan
has not relied primarily on any advice or recommendation of the Company or any of its affiliates;

 

		bb.	Anti-Money Laundering; OFAC.

 

[The
Subscriber should check the Office of Foreign Assets Control (“OFAC”) website at http://www.treas.gov/ofac
before making the following representations.] The Subscriber represents that the amounts invested by it in the Company in
the Units were not and are not directly or indirectly derived from activities that contravene U.S. federal or state or
international laws and regulations, including anti-money laundering laws and regulations. U.S. federal regulations and
executive orders administered by OFAC prohibit, among other things, the engagement in transactions with, and the provision of
services to, certain foreign countries, territories, entities and individuals. The lists of OFAC prohibited countries,
territories, persons and entities can be found on the OFAC website at http://www.treas.gov/ofac. In addition, the programs
administered by OFAC (the “OFAC Programs”) prohibit dealing with individuals1 or
entities in certain countries regardless of whether such individuals or entities appear on the OFAC lists.

 

 

 

		1	These
individuals include specially designated nationals, specially designated narcotics traffickers and other parties subject to OFAC
sanctions and embargo programs.

 

    	20 

     

    

 

To the best
of the Subscriber’s knowledge, none of: (1) the Subscriber; (2) any person controlling or controlled by the Subscriber; (3)
if the Subscriber is a privately-held entity, any person having a beneficial interest in the Subscriber; or (4) any person for
whom the Subscriber is acting as agent or nominee in connection with this investment is a country, territory, individual or entity
named on an OFAC list, or a person or entity prohibited under the OFAC Programs. Please be advised that the Company may not accept
any amounts from a prospective investor if such prospective investor cannot make the representation set forth in the preceding
paragraph. The Subscriber agrees to promptly notify the Company should the Subscriber become aware of any change in the information
set forth in these representations. The Subscriber understands and acknowledges that, by law, the Company may be obligated to “freeze
the account” of the Subscriber, either by prohibiting additional subscriptions from the Subscriber, declining any
redemption requests and/or segregating the assets in the account in compliance with governmental regulations, and a Broker may
also be required to report such action and to disclose the Subscriber’s identity to OFAC. The Subscriber further acknowledges
that the Company may, by written notice to the Subscriber, suspend the redemption rights, if any, of the Subscriber if the Company
reasonably deems it necessary to do so to comply with anti-money laundering regulations applicable to the Company or any Broker
or any of the Company’s other service providers. These individuals include specially designated nationals, specially designated
narcotics traffickers and other parties subject to OFAC sanctions and embargo programs.

 

To the best
of the Subscriber’s knowledge, none of: (1) the Subscriber; (2) any person controlling or controlled by the Subscriber;
(3) if the Subscriber is a privately-held entity, any person having a beneficial interest in the Subscriber; or (4) any person
for whom the Subscriber is acting as agent or nominee in connection with this investment is a senior foreign political figure2, or any immediate family3 member or close associate4 of a senior foreign political figure,
as such terms are defined in the footnotes below.

 

If the Subscriber
is affiliated with a non-U.S. banking institution (a “Foreign Bank”), or if the Subscriber receives deposits from,
makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, the Subscriber represents and warrants
to the Company that: (1) the Foreign Bank has a fixed address, other than solely an electronic address, in a country in which the
Foreign Bank is authorized to conduct banking activities; (2) the Foreign Bank maintains operating records related to its banking
activities; (3) the Foreign Bank is subject to inspection by the banking authority that licensed the Foreign Bank to conduct banking
activities; and (4) the Foreign Bank does not provide banking services to any other Foreign Bank that does not have a physical
presence in any country and that is not a regulated affiliate.

 

		dd.	Each Subscriber is aware that some of the members of Intuitive Venture Partners, LLC (“Intuitive”)
are registered representatives registered with GPN, and may receive a portion of the Placement Agent Cash Fee and/or Placement
Agent Warrants as described above. Intuitive is also acting as Collateral Agent. Each Subscriber, for itself and on behalf of its
affiliates, expressly waives any conflicts of interest or potential conflicts of interest discussed in this paragraph and agrees
that neither GPN nor the Collateral Agent or their affiliates, officers, directors or members shall have any liability to the Subscriber
or its affiliates, and the Subscriber and its affiliates shall have no liability to GPN, the Collateral Agent or their affiliates,
officers, directors or members, with respect to such conflicts of interest or potential conflicts of interest.

 

 

 

		2	A “senior foreign political figure” is defined as a senior official in the executive,
legislative, administrative, military or judicial branches of a foreign government (whether elected or not), a senior official
of a major foreign political party, or a senior executive of a foreign government-owned corporation. In addition, a “senior
foreign political figure” includes any corporation, business or other entity that has been formed by, or for the benefit
of, a senior foreign political figure.

 

		3	“Immediate family” of a senior foreign political figure typically includes the figure’s
parents, siblings, spouse, children and in-laws.

 

		4	A “close associate” of a senior foreign political figure is a person who is widely and publicly known to maintain
an unusually close relationship with the senior foreign political figure, and includes a person who is in a position to conduct
substantial domestic and international financial transactions on behalf of the senior foreign political figure.

  

    	21 

     

    

 

6.    Covenants.

 

		(a)	Best Efforts. Each party shall use its best efforts timely to satisfy each of the conditions
to be satisfied by it as provided in Sections 7 and 8 of this Agreement.

 

		(b)	Form D. The Company agrees to file a Form D with respect to the offer and sale of the Notes
and Warrants as required under Regulation D. The Company shall take such action as the Company shall reasonably determine is necessary
to qualify the Notes, Warrants, Conversion Shares and Warrant Shares, or obtain an exemption for the Notes, Warrants, Conversion
Shares and Warrant Shares for sale to the Subscribers at the Closing pursuant to this Agreement under applicable securities or
“Blue Sky” laws of the states of the United States and foreign jurisdictions, as applicable.

 

		(c)	Reporting Status. Until the date on which the Subscriber shall have sold all of Subscriber’s
Conversion Shares and Warrants Shares, the Company shall file in a timely manner (or, with respect to Form 8-K reports, shall use
its commercially reasonable efforts to file in a timely manner) all reports required to be filed with the SEC pursuant to the Exchange
Act, and the regulations of the SEC thereunder, and the Company shall not terminate its status as an issuer required to file reports
under the Exchange Act even if the Exchange Act or the rules and regulations thereunder would otherwise permit such termination.

 

		(d)	Use of Proceeds. The Company shall use the net proceeds from the sale of the Units (after
deducting fees and expenses (including brokerage fees, legal fees and expenses and fees payable to the Escrow Agent)) for research
and development expenses, working capital and general corporate purposes.

 

		(e)	Listings or Quotation. The Company shall use its commercially reasonable efforts to maintain
the listing or quotation of its Common Stock upon the OTCQB tier of the OTC marketplace.

 

		(f)	Survival. The representations and warranties of the Company and the Subscriber contained
in Sections 4 and 5 shall survive the Closing for a period of twenty-four (24) months. The covenants contained in Sections 6 and
15 shall survive for the maximum period permitted by law. Each Subscriber shall be responsible only for its own representations,
warranties, agreements and covenants hereunder.

 

    	22 

     

    

 

		(g)	Authority of Collateral Agent. Subscriber hereby irrevocably appoints, designates and authorizes
the Collateral Agent to take such action on its behalf under the provisions of the Security Agreement and to exercise such powers
and perform such duties as are expressly delegated to it by the terms of the Security Agreement, together with such powers as are
reasonably incidental thereto, and grants and affirms the immunities and indemnities provided to the Collateral Agent Related Persons
(as defined below) and their affiliates in the Security Agreement. Notwithstanding any provision to the contrary contained elsewhere
in this Agreement or in the Security Agreement, the Collateral Agent shall not have any duties or responsibilities, except those
expressly set forth in the Security Agreement, and no implied covenants, functions, responsibilities, duties, obligations or liabilities
shall be read into this Agreement or the Security Agreement or otherwise exist against the Collateral Agent in its capacity as
such. Subscriber acknowledges that none of the Collateral Agent Related Persons has made any representation or warranty to it,
and that no act by the Collateral Agent hereinafter taken, including any review of the affairs of the Company, shall be deemed
to constitute any representation or warranty by any Collateral Agent Related Person to Subscriber. Subscriber represents to the
Collateral Agent that it has, independently and without reliance upon any Collateral Agent Related Person and based on such documents
and information as it has deemed appropriate, made its own appraisal of, and investigation into, the business, prospects, operations,
property, financial and other condition and creditworthiness of the Company and made its own decision to enter into this Agreement
and to invest in the Unit. Subscriber also represents that it will, independently and without reliance upon any Collateral Agent
Related Person and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit
analysis, appraisals and decisions in taking or not taking action under this Agreement and the other Transaction Documents, and
to make such investigations as it deems necessary to inform itself as to the business, prospects, operations, property, financial
and other condition and creditworthiness of the Company. Except for notices, reports and other documents expressly required by
the Security Agreement or this Agreement to be furnished to the Subscriber by the Collateral Agent, the Collateral Agent in its
capacity as such shall not have any duty or responsibility to provide Subscriber with any credit or other information concerning
the business, prospects, operations, property, financial and other condition or creditworthiness of the Company which may come
into the possession of any of the Collateral Agent Related Persons. “Collateral Agent Related Persons”
means the Collateral Agent and any successor agent arising hereunder or under the Security Agreement, together with their respective
affiliates, and the officers, directors, employees, agents and attorneys-in-fact of such persons and affiliates.

 

7.    Conditions
to Company’s Obligations at Closing. The Company’s obligation to complete the sale and issuance of the Units and
deliver the Notes and the Warrants to each Subscriber, individually, at each Closing shall be subject to the following conditions
to the extent not waived by the Company:

 

		a.	Receipt of Payment. The Company shall have received payment, by certified or other bank
check or by wire transfer of immediately available funds, in the full amount of the Purchase Price for the number of Units being
purchased by such Subscriber at such Closing.

 

		b.	Representations and Warranties. The representations and warranties made by the Subscriber
in Section 5 hereof shall be true and correct in all material respects as of, and as if made on, the date of this Agreement and
as of such Closing Date with the same force and effect as if they had been made on and as of said date (except in each case to
the extent any such representation and warranty is qualified by materiality, in which case, such representation and warranty shall
be true and correct in all respects as so qualified). The Subscriber shall have performed in all material respects all obligations
and covenants herein required to be performed by them on or prior to such Closing Date.

 

    	23 

     

    

 

		c.	Receipt of Executed Documents. Such Subscriber shall have executed and delivered to the
Company the Omnibus Signature Page, the Investor Profile, Anti-Money Laundering Form and Accredited Investor Certification.

 

		d.	Minimum Offering. The initial Closing shall be at least for the number of Units in the Minimum
Offering at the Purchase Price.

 

		e.	Judgments. No judgment, writ, order, injunction, award or decree of or by any court, or
judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall
have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing
the consummation of the transactions contemplated hereby.

 

8.    Conditions
to Subscribers’ Obligations at Closing. Each Subscriber’s obligation to accept delivery of the Notes and the Warrants
and to pay for the Units at each Closing shall be subject to the following conditions to the extent not waived by the Placement
Agents on behalf of the Subscribers:

 

		a.	Representations and Warranties. The representations and warranties made by the Company in
Section 4 hereof shall be true and correct in all material respects (except to the extent any such representation and warranty
is qualified by materiality or reference to Material Adverse Effect, in which case, such representation and warranty shall be true
and correct in all respects as so qualified) as of, and as if made on, the date of this Agreement and as of such Closing Date with
the same force and effect as if they had been made on and as of said date, except to the extent any such representation or warranty
expressly speaks as of an earlier date, in which case such representation or warranty shall be true and in all material respects
correct as of such earlier date (except in each case to the extent any such representation and warranty is qualified by materiality
or reference to Material Adverse Effect, in which case, such representation and warranty shall be true and correct in all respects
as so qualified). The Company shall have performed in all material respects all obligations and covenants herein required to be
performed by it on or prior to such Closing Date.

 

		b.	Receipt of Executed Transaction Documents. The Company shall have executed and delivered
to the Placement Agents the Registration Rights Agreement and the Escrow Agreement.

 

		c.	Minimum Offering. The initial Closing shall be at least for the number of shares of Common
Stock in the Minimum Offering at the Purchase Price.

 

		d.	Judgments. No judgment, writ, order, injunction, award or decree of or by any court, or
judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall
have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing
the consummation of the transactions contemplated hereby.

 

    	24 

     

    

 

		e.	Consents. The Company shall have obtained any and all consents, permits, approvals, registrations
and waivers necessary or appropriate for consummation by the Company of the purchase and sale of the Units and the transactions
contemplated hereby or under the Transaction Documents, all of which shall be in full force and effect.

 

		f.	President’s Certificate. The Subscribers shall have received a certificate, executed
by the President of the Company, dated as of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably
requested by the Subscribers.

 

		g.	Officer’s Certificate. The Company shall have delivered to the Subscribers a certificate,
executed on its behalf by an appropriate officer, dated as of the Closing Date, certifying the resolutions adopted by its Board
of Directors approving the transactions contemplated by this Agreement, the other Transaction Documents and the issuance of the
Units, certifying the current versions of its Certificate of Incorporation and By-laws (or equivalent documents), certifying as
to the good standing of the Company in the jurisdiction of its formation and in jurisdictions authorized to conduct business, and
certifying as to the signatures and authority of persons signing this Agreement on behalf of the Company. The foregoing certificate
shall only be required to be delivered on the First Closing Date, unless any information contained in the certificate has changed.

 

		h.	Legal Opinion. Solely with respect to the First Closing, Duane Morris LLP, counsel to the
Company, shall deliver an opinion addressed to the Subscribers and the Placement Agents, dated as of the date of the First Closing,
in form and substance reasonably acceptable to the Subscribers and Placement Agent.

 

9.     Indemnification.
The Subscriber agrees to indemnify and hold harmless the Company, the Placement Agent and any other broker, agent or finder engaged
by the Company for the Offering, and their respective directors, officers, shareholders, members, partners, employees and agents
(and any other persons with a functionally equivalent role of a person holding such titles notwithstanding a lack of such title
or any other title), each person who controls such persons (within the meaning of Section 15 of the Securities Act and Section
20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other persons
with a functionally equivalent role of a person holding such titles notwithstanding a lack of such title or any other title) of
such controlling person, from and against all losses, liabilities, claims, damages, costs, fees and expenses whatsoever (including,
but not limited to, any and all expenses incurred in investigating, preparing or defending against any litigation commenced or
threatened) based upon or arising out of the Subscriber’s actual or alleged false acknowledgment, representation or warranty,
or misrepresentation or omission to state a material fact, or breach by the Subscriber of any covenant or agreement made by the
Subscriber, contained herein or in any other any other documents delivered by the Subscriber to the Company in connection with
the transactions contemplated by this Agreement.

 

    	25 

     

    

 

The Company agrees
to indemnify and hold harmless the Subscriber, its directors, officers, shareholders, members, partners, employees and agents (and
any other persons with a functionally equivalent role of a person holding such titles notwithstanding a lack of such title or any
other title), each person who controls such persons (within the meaning of Section 15 of the Securities Act and Section 20 of the
Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other persons with a
functionally equivalent role of a person holding such titles notwithstanding a lack of such title or any other title) of such controlling
person, from and against all losses, liabilities, claims, damages, costs, fees and expenses whatsoever (including, but not limited
to, any and all expenses incurred in investigating, preparing or defending against any litigation commenced or threatened) based
upon or arising out of the Company’s actual or alleged false acknowledgment, representation or warranty, or misrepresentation
or omission to state a material fact, or breach by the Company of any covenant or agreement made by the Company, contained herein
or in any other any other documents delivered by the Company to the Subscriber in connection with the transactions contemplated
by this Agreement.

 

10.  Revocability;
Binding Effect. The subscription hereunder may be revoked prior to the Closing thereon, provided that written notice of revocation
is sent and is received by the Company or either of the Placement Agents at least two Business Days prior to the Closing on such
subscription. The Subscriber hereby acknowledges and agrees that this Agreement shall survive the death or disability of the Subscriber
and shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal
representatives and permitted assigns. If the Subscriber is more than one person, the obligations of the Subscriber hereunder shall
be joint and several and the agreements, representations, warranties and acknowledgments herein shall be deemed to be made by and
be binding upon each such person and such person’s heirs, executors, administrators, successors, legal representatives and
permitted assigns.

 

11.  Immaterial
Modifications to the Registration Rights Agreement. The Company may, at any time prior to the initial Closing, amend the Registration
Rights Agreement if necessary to clarify any provision therein, without first providing notice or obtaining prior consent of the
Subscriber.

 

12.  Third-Party
Beneficiary. The Placement Agents shall be an express third-party beneficiary of the representations and warranties included
in this Agreement. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth
in this Section 11.

 

13.  Assignability.
This Agreement and the rights, interests and obligations hereunder are not transferable or assignable by the Subscriber, and the
transfer or assignment of the Units, the Notes, the Conversion Shares, the Warrants or the Warrant Shares shall be made only in
accordance with all applicable laws.

 

14.  Applicable
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without reference
to the principles thereof relating to the conflict of laws.

 

15.  Arbitration.
The parties agree to submit all controversies to arbitration in accordance with the provisions set forth below and understand
that:

 

		a.	Arbitration shall be final and binding on the parties.

 

		b.	The parties are waiving their right to seek remedies in court, including the right to a jury trial.

 

    	26 

     

    

 

		c.	Pre-arbitration discovery is generally more limited and different from court proceedings.

 

		d.	The arbitrator’s award is not required to include factual findings or legal reasoning and
any party’s right to appeal or to seek modification of rulings by arbitrators is strictly limited.

 

		e.	The panel of arbitrators will typically include a minority of arbitrators who were or are affiliated
with the securities industry.

 

		f.	All controversies which may arise between the parties concerning this Agreement shall be determined
by arbitration pursuant to the rules then pertaining to the Financial Industry Regulatory Authority in New York City, New York.
Judgment on any award of any such arbitration may be entered in the Supreme Court of the State of New York or in any other court
having jurisdiction of the person or persons against whom such award is rendered. Any notice of such arbitration or for the confirmation
of any award in any arbitration shall be sufficient if given in accordance with the provisions of this Agreement. The parties agree
that the determination of the arbitrators shall be binding and conclusive upon them. The prevailing party, as determined by such
arbitrators, in a legal proceeding shall be entitled to collect any costs, disbursements and reasonable attorney’s fees from
the other party. Prior to filing an arbitration, the parties hereby agree that they will attempt to resolve their differences first
by submitting the matter for resolution to a mediator, acceptable to all parties, and whose expenses will be borne equally by all
parties. The mediation will be held in the County of New York, State of New York, on an expedited basis. If the parties cannot
successfully resolve their differences through mediation, within sixty (60) days from the receipt of written notice of a controversy
from the notifying party, the matter will be submitted for resolution by arbitration. The arbitration shall take place in the County
of New York, State of New York, on an expedited basis.

 

16.  Blue
Sky Qualification. The purchase of Units under this Agreement is expressly conditioned upon the exemption from qualification
of the offer and sale of the Units from applicable federal and state securities laws. The Company shall not be required to qualify
this transaction under the securities laws of any jurisdiction and, should qualification be necessary, the Company shall be released
from any and all obligations to maintain its offer, and may rescind any sale contracted, in the jurisdiction.

 

17.  Use
of Pronouns. All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, neuter,
singular or plural as the identity of the person or persons referred to may require.

 

18.  Confidentiality.
The Subscriber acknowledges and agrees that any information or data the Subscriber has acquired from or about the Company or
may acquire in the future, not otherwise properly in the public domain, was received in confidence. The Subscriber agrees not to
divulge, communicate or disclose, except as may be required by law or for the performance of this Agreement, or use to the detriment
of the Company or for the benefit of any other person, or misuse in any way, any confidential information of the Company, including
any scientific, technical, trade or business secrets of the Company and any scientific, technical, trade or business materials
that are treated by the Company as confidential or proprietary, including, but not limited to, internal personnel and financial
information of the Company or its affiliates, the manner and methods of conducting the business of the Company or its affiliates
and confidential information obtained by or given to the Company about or belonging to third parties. The Subscriber understands
that the Company may rely on Subscriber’s agreement of confidentiality to comply with the exemptive provisions of Regulation
FD under the Securities Act of 1933 as set forth in Rule 100(a)(b)(2)(ii) of Regulation FD. In addition, the Subscriber acknowledges
that it is aware that the United States securities laws generally prohibit any person who is in possession of material nonpublic
information about a public company such as the Company from purchasing or selling securities of such company. The provisions of
this Section are in addition to and not in replacement of any other confidentiality agreement between the Company and the Subscriber.

 

    	27 

     

    

 

19.  Right
of First Refusal.

 

		a.	In the event that after the Offering Termination Date and prior to the date that is twelve (12)
months following the initial Closing, the Company determines to offer for sale or to accept an offer to purchase any Company securities,
including both debt and equity securities (the “Subsequent Offering Securities”), each Subscriber who
previously purchased Units in the Offering (a “ROFR Holder”) shall have an option to purchase such ROFR Option Holder’s
pro rata share of Subsequent Offering Securities on the same terms and conditions on which the Subsequent Offering Securities are
proposed to be issued, as set forth in this Section (the “ROFR”).

 

		b.	The Company shall send to each ROFR Holder a written notice (the “ROFR Notice”).
The ROFR Notice shall set forth the material terms of the proposed sale of Subsequent Offering Securities and the number of Subsequent
Offering Securities such ROFR Holder has the ROFR to purchase (such ROFR Holder’s “ROFR Amount”),
which shall be a percentage of the total number of Subsequent Offering Securities proposed to be sold equal to (i) the total number
of Units previously purchased by such ROFR Holder divided by (ii) the total number of Units previously sold by the Company; and
the ROFR Notice shall include a copy of this Section. Each ROFR Holder wishing to exercise its ROFR on all or part of its ROFR
Amount shall so notify the Company in writing within ten (10) Business Days after the Company’s transmittal of the ROFR Notice
(a “ROFR Exercise Notice”).

 

		c.	If the amount of Subsequent Offering Securities elected to be purchased in all ROFR Exercise Notices
is less than the total number set forth in the ROFR Notice, the Company may sell the excess shares to persons other than ROFR Holders,
but only on substantially the same terms as set forth in the First ROFR Notice. ROFR Holders who have elected to purchase shares
of Subsequent Offering Securities shall execute the subscription and other related agreements for the sale of the Subsequent Offering
Securities, the closing of which shall occur as provided in such documents.

 

		d.	Notwithstanding the foregoing, the ROFR shall not apply to Company securities issued (i) pursuant
to any merger, acquisition, stock or asset purchase, or business combination transactions involving the Company (a “Strategic
Transaction”); or (ii) to any investors in connection with any such Strategic Transaction where the raising of capital
is a condition to such transaction.

 

    	28 

     

    

 

20.  Potential
Conflicts. The Placement Agents, their sub-agents, legal counsels to the Placement Agents, and/or their respective affiliates,
principals, representatives or employees may now or hereafter own shares of the Company.

 

21.  Independent
Nature of Each Purchaser’s Obligations and Rights. For avoidance of doubt, the obligations of the Purchasers under this
Agreement are several and not joint with the obligations of any other Purchasers, and each Purchaser shall not be responsible in
any way for the performance of the obligations of any other Purchaser under any other Subscription Agreement. Nothing contained
herein and no action taken by the Purchaser shall be deemed to constitute the Purchaser as a partnership, an association, a joint
venture, or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by this Agreement and any other Subscription Agreements. The
Purchaser shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out
of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding
for such purpose.

 

22.  Notices.
All notice and other communications hereunder which are required or permitted under this Agreement will be in writing and shall
be deemed effectively given to a party by (a) the date of transmission if sent by facsimile or e-mail with confirmation of transmission
by the transmitting equipment if such notice or communication is delivered prior to 5:00 P.M., New York City time, on a business
day, or the next business day after the date of transmission, if such notice or communication is delivered on a day that is not
a business day or later than 5:00 P.M., New York City time, on any business day; (b) seven days after deposit with the United States
Post Office, by certified mail, return receipt requested, first-class mail, postage prepaid; (c) on the date delivered, if delivered
by hand or by messenger or overnight courier, addressee signature required (costs prepaid), to the addresses below or at such other
address and/or to such other persons as shall have been furnished by the parties:

	 	 
	If to the Company: 	Enumeral Biomedical Holdings, Inc.
	 	200 CambridgePark Drive, Suite 2000
	 	Cambridge, MA 02140
	 	Attention: General Counsel
	 	 
	With a copy to:	Duane Morris LLP
	(which shall not constitute notice)	1540 Broadway
	 	New York, NY 10036
	 	Attention: Michael D. Schwamm, Esq.
	 	 
	If to Katalyst Securities LLC:	Katalyst Securities, LLC
	 	630 Third Avenue, 5th Floor
	 	New York, NY 10017
	 	Attention: Michael Silverman, Managing Director
	 	 
	With a copy to: 	Barbara J. Glenns, Esq.
	(which shall not constitute notice)	Law Office of Barbara J. Glenns, Esq.
	 	30 Waterside Plaza, Suite 25G
	 	New York, NY 10010

  

    	29 

     

    

 

	If to GP Nurmenkari Inc.:	GP Nurmenkari Inc.
	 	64 Wall Street, Suite 402
	 	Norwalk, CT 06850
	 	Attention: Albert Pezone
	 	 
	With a copy to: 	CKR Law LLP
	 (which shall not constitute notice)

	1330 Avenue of the Americas
	 	14th Floor
	 	New York, NY 10019
	 	Attention: Scott Rapfogel, Esq.

 

23.  Omnibus
Signature Page. This Agreement is intended to be read and construed in conjunction with the Registration Rights Agreement and
the Security Agreement. Accordingly, pursuant to the terms and conditions of this Agreement, the Registration Rights Agreement
and the Security Agreement, it is hereby agreed that the execution by the Subscriber of this Agreement, in the place set forth
on the Omnibus Signature Page below, shall constitute agreement to be bound by the terms and conditions hereof, and the terms and
conditions of the Registration Rights Agreement and the Security Agreement, with the same effect as if each of such separate but
related agreement were separately signed.

 

24.  Public
Disclosure. Neither the Subscriber nor any officer, manager, director, member, partner, stockholder, employee, affiliate, affiliated
person or entity of the Subscriber shall make or issue any press releases or otherwise make any public statements or make any disclosures
to any third person or entity with respect to the transactions contemplated herein and will not make or issue any press releases
or otherwise make any public statements of any nature whatsoever with respect to the Company without the Company’s express
prior approval. The Company has the right to withhold such approval in its sole discretion.

 

25.  Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

26.  Modification.
This Agreement shall not be amended, modified or waived except by an instrument in writing signed by the Company and the holders
of at least a majority of the Units, if no Notes or Warrants have yet been converted or exercised. If all of the Notes and Warrants
have been converted and exercised, this Agreement shall not be amended, modified or waived except by an instrument in writing signed
by the Company and the holders of at least a majority of the Conversion Shares and Warrant Shares acting as a group. If some but
not all of the Notes and Warrants have been converted and exercised such that there are outstanding both full Units on the one
hand and Conversion Shares and Warrant Shares on the other, this Agreement shall not be amended, modified or waived except by an
instrument in writing signed by the Company , the holders of at least a majority of the Units and the holders of at least a majority
of the Conversion Shares and Warrant Shares acting as a group. Any amendment, modification or waiver effected in accordance with
this Section 26 shall be binding upon the Subscriber and each transferee of Notes, Warrants, Conversion Shares or Warrant Shares,
each future holder of all such Notes, Warrants, Conversion Shares or Warrant Shares, and the Company but with respect to holders
of Conversion Shares and Warrant Shares only to be extent such Conversion Shares and Warrant Shares, as applicable, have not been
previously sold.

 

    	30 

     

    

 

27.   Miscellaneous.

 

		a.	This Agreement, together with the Registration Rights Agreement, the Note, the Warrant, the Security
Agreement, and any confidentiality agreement between the Purchaser and the Company, constitutes the entire agreement between the
Subscriber and the Company with respect to the Offering and supersedes all prior oral or written agreements and understandings,
if any, relating to the subject matter hereof. The terms and provisions of this Agreement may be waived, or consent for the departure
therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or provisions.

 

		b.	This Agreement may be executed in one or more original or facsimile or by an e-mail which contains
a portable document format (.pdf) file of an executed signature page counterparts, each of which shall be deemed an original, but
all of which shall together constitute one and the same instrument and which shall be enforceable against the parties actually
executing such counterparts. The exchange of copies of this Agreement and of signature pages by facsimile transmission or in .pdf
format shall constitute effective execution and delivery of this Agreement as to the parties and may be used in lieu of the original
Agreement for all purposes. Signatures of the parties transmitted by facsimile or by e-mail of a document in pdf format shall be
deemed to be their original signatures for all purposes.

 

		c.	Each provision of this Agreement shall be considered separable and, if for any reason any provision
or provisions hereof are determined to be invalid or contrary to applicable law, such invalidity or illegality shall not impair
the operation of or affect the remaining portions of this Agreement.

 

		d.	Paragraph titles are for descriptive purposes only and shall not control or alter the meaning of
this Agreement as set forth in the text.

 

		e.	The Subscriber understands and acknowledges that there may be multiple Closings for the Offering.

 

		f.	The Subscriber hereby agrees to furnish the Company such other information as the Company may request
prior to the Closing with respect to its subscription hereunder.

 

[Signature
Page Follows]

 

    	31 

     

    

 

IN WITNESS WHEREOF,
the Company has duly executed this Subscription Agreement as of the 19th day of May, 2017.

 

	 	ENUMERAL
BIOMEDICAL HOLDINGS, INC.	 
	 	 	 
	 	By: 		 
	 	 	Name: Kevin G. Sarney
Title:  Vice President
of Finance, Chief Accounting Officer, and Treasurer 	 

  

    	 

     

    

 

How
to subscribe for Units in the private offering of

Enumeral
Biomedical Holdings, Inc.:

 

		1.	Date
                                         and Fill in the number of Units being purchased and complete and sign the
                                         Omnibus Signature Page.

 

		2.	Initial
                                         the Accredited Investor Certification in the appropriate place or places.

 

		3.	Complete
                                         and sign the Investor Profile.

 

		4.	Complete
                                         and sign the Anti-Money Laundering Information Form.

 

		5.	Date
                                         and sign the Confidentiality Agreement.

 

		6.	Fax
                                         or email all forms and then send all signed original documents to your registered
                                         representatives office:

 

	Katalyst
                                         Securities LLC:

        Attn:  Jennifer
        Goro

        630
        Third Avenue, 5th Floor

        New
        York, NY 10017

        Facsimile
        Number:  212.247.1059

        Telephone
        Number:  212.400.6993

        E-mail
        address:  jag@katalystsecurities.com

         
	 	GP
                                         Nurmenkari Inc.

        Attn:  Kimberly
        J Bechtle

        122
        East 42nd Street, Suite 1616

        New
        York, NY 10168

        Facsimile
        Number:  212.661.8786

        Telephone
        Number:  212.612.3219

        E-mail
        address:  kbechtle@intuitivevp.com

         

		7.	If
                                         you are paying the Purchase Price by check, a certified or other bank check for
                                         the exact dollar amount of the Purchase Price for the number of Shares you are purchasing
                                         should be made payable to the order of “Delaware Trust Company], as Escrow Agent
                                         for Enumeral Biomedical Holdings, Inc., Acct. # 79-2997” and should be sent
                                         directly to Delaware Trust Company, 2711 Centerville Road, One Little Falls Centre,
                                         Wilmington, DE 19808, Attn: Alan R. Halpern.

 

Checks
take up to 5 business days to clear. A check must be received by the Escrow Agent at least 6 business days before the closing
date.

 

		8.	If
                                         you are paying the Purchase Price by wire transfer, you should send a wire transfer
                                         for the exact dollar amount of the Purchase Price for the number of Shares you are purchasing
                                         according to the following instructions:

 

	Bank:

         
	PNC
                                         Bank

        300
        Delaware Avenue

        Wilmington,
        DE 19899

	ABA
    Routing #:	031100089
	SWIFT
    CODE:	PNCCUS33
	Account
    Name:	Delaware
    Trust Company
	Account
    #:	5605012373
	Reference:	“FFC:
                                         Enumeral Biomedical Holdings, Inc., Subscription Escrow #4 Acct. # 79-2997

        [INSERT
        SUBSCRIBER’S NAME]”

	Delaware
    Trust Contact:	Alan
    R. Halpern

 

Thank
you for your interest,

 

Enumeral
Biomedical Holdings, Inc.

 

    	 

     

    

 

OMNIBUS
SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT, REGISTRATION RIGHTS AGREEMENT AND SECURITY AGREEMENT

 

The
undersigned, desiring to: (i) enter into the Subscription Agreement, dated as of ____________ ___,1 2017 (the “Subscription
Agreement”), between the undersigned, Enumeral Biomedical Holdings, Inc., a Delaware corporation (the “Company”),
and the other parties thereto, in or substantially in the form furnished to the undersigned (ii) purchase the Notes and Warrants
of the Company as set forth in the Subscription Agreement, (iii) enter into the Registration Rights Agreement (the “Registration
Rights Agreement”), among the undersigned, the Company and the other parties thereto, in or substantially in the
form furnished to the undersigned, and (iv) enter into the Intellectual Property Security Agreement (the “Security
Agreement”) among the undersigned, the Company, Enumeral Biomedical Corp. and Intuitive Venture Partners, LLC and
the other parties thereto, in or substantially in the form furnished to the undersigned, hereby agrees to purchase such securities
from the Company and further agrees to join the Subscription Agreement, the Registration Rights Agreement and the Security Agreement
as a party thereto, with all the rights and privileges appertaining thereto, and to be bound in all respects by the terms and
conditions thereof. The undersigned specifically acknowledges having read the representations section in the Subscription Agreement
entitled “Representations, Warranties and Agreements of the Subscriber” and hereby represents that the statements
contained therein are complete and accurate with respect to the undersigned as a Subscriber.

 

IN
WITNESS WHEREOF, the Subscriber hereby executes this Agreement, the Registration Rights Agreement and the Security Agreement.

 

Dated: _________________________,
2017

 

	_______________ 

        Number
        of Units
	X	$     1,000      

        Purchase
        Price per Unit
	=	$_______________

        Total
        Purchase Price

 

	SUBSCRIBER
    (individual)	 	SUBSCRIBER
    (entity)
	 	 	 
	Signature	 	Name
    of Entity
	 	 	 
	 	 	By:	 
	Print
    Name	 	   Signature

 

	 	 	 
	 	 	Print
    Name:	 
	Signature
    (if Joint Tenants or Tenants in Common)	 	Title:	 	 
	 	 	 
	Address
    of Principal Residence:	 	Address
    of Executive Offices:
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Social
    Security Number(s):	 	IRS
    Tax Identification Number:
	 	 	 
	 	 	 
	Telephone
    Number:	 	Telephone
    Number:
	 	 	 
	 	 	 
	Facsimile
    Number:	 	Facsimile
    Number:
	 	 	 
	 	 	 
	E-mail
    Address:	 	E-mail
    Address:
	 	 	 

 

 

1
Will reflect the Closing Date. Not to be completed by Purchaser.

 

    	 

     

    

 

Enumeral
Biomedical Holdings, Inc.

 

ACCREDITED
INVESTOR CERTIFICATION

 

For
Individual Investors Only

(all
Individual Investors must INITIAL where appropriate):

 

	Initial
    _______	I
    have a net worth of at least US$1 million either individually or through aggregating my individual holdings and those in which
    I have a joint, community property or other similar shared ownership interest with my spouse. (For purposes of calculating
    your net worth under this paragraph, (a) your primary residence shall not be included as an asset; (b) indebtedness
    secured by your primary residence, up to the estimated fair market value of your primary residence at the time of your purchase
    of the securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the
    time of your purchase of the securities exceeds the amount outstanding sixty (60) days before such time, other than as a result
    of the acquisition of your primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness
    that is secured by your primary residence in excess of the estimated fair market value of your primary residence at the time
    of your purchase of the securities shall be included as a liability.)
	Initial
    _______	I
    have had an annual gross income for the past two (2) years of at least US$200,000 (or US$300,000 jointly with my spouse) and
    expect my income (or joint income, as appropriate) to reach the same level in the current year.
	 	 
	Initial
    _______	I
    am a director or executive officer of Enumeral Biomedical Holdings, Inc.
	 	 
	For
    Non-Individual Investors (Entities)
	(all
    Non-Individual Investors must INITIAL where appropriate):
	 	 
	Initial
    _______	The
    investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by
    persons who meet at least one of the criteria for Individual Investors set forth above (in which case each such person must
    complete the Accreditor Investor Certification for Individuals above as well the remainder of this questionnaire). 
	 	 
	Initial
    _______	The
    investor certifies that it is a partnership, corporation, limited liability company or business trust that has total assets
    of at least US$5 million and was not formed for the purpose of investing the Company.
	 	 
	Initial
    _______	The
    investor certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in
    ERISA §3(21)) that is a bank, savings and loan association, insurance company or registered investment advisor.
	 	 
	Initial
    _______	The
    investor certifies that it is an employee benefit plan whose total assets exceed US$5,000,000 as of the date of this Agreement.
	 	 
	Initial
    _______	The
    undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons
    who meet at least one of the criteria for Individual Investors.
	 	 
	Initial
    _______	The
    investor certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its
    individual or fiduciary capacity.
	 	 
	Initial
    _______	The
    undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934.
	 	 
	Initial
    _______	The
    investor certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets
    exceeding US$5,000,000 and not formed for the specific purpose of investing in the Company.
	 	 
	Initial
    _______	The
    investor certifies that it is a trust with total assets of at least US$5,000,000, not formed for the specific purpose of investing
    in the Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters
    that such person is capable of evaluating the merits and risks of the prospective investment.
	 	 
	Initial
    _______	The
    investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or
    instrumentality thereof, for the benefit of its employees, and which has total assets in excess of US$5,000,000.
	 	 
	Initial
    _______	The
    investor certifies that it is an insurance company as defined in §2(13) of the Securities Act of 1933, or a registered
    investment company.

 

    	 

     

    

 

Enumeral
Biomedical Holdings, Inc.

 

INVESTOR
PROFILE

(Must be completed by Investor)

 

Section
A - Personal Investor Information

 

	Investor
    Name(s): 	  

 

	Individual
    executing Profile or Trustee:  	  

	 	 
	Social
                                         Security Numbers / Federal I.D. Number:	 

 

	Date of Birth:	 	 	 	Marital
    Status:	 

	Joint
    Party Date of Birth:	 	 	  Investment
    Experience (Years):	 

	Annual
    Income:	 	 	Liquid
    Net Worth:	 
	 	 	 	 

	Net
    Worth*:	 	 	 

 

Tax
Bracket:                               _____
15% or below                                           _____
25% - 27.5%                                            _____
Over 27.5%

 

	Home
                                         Street Address:  	  

 

	Home
                                         City, State & Zip Code:  	  

 

Home
Phone: ___________________________     Home Fax: ___________________________    Home Email:
___________________________

 

	Employer:  	  

 

	Employer
    Street Address:  	  

 

	Employer
    City, State & Zip Code:  	  

 

Bus.
Phone: _________________________   Bus. Fax: _________________________   Bus. Email: _________________________   

 

	Type
                                         of Business:  	  

 

	Outside
    Broker/Dealer:  	  

 

Section
B – Certificate Delivery Instructions

 

____
Please deliver certificate to the Employer Address listed in Section A.

 

____
Please deliver certificate to the Home Address listed in Section A.

 

	____
    Please deliver certificate to the following address:  	  

 

Section
C – Form of Payment – Check or Wire Transfer

 

____
Check payable to Delaware Trust Company, as Escrow Agent for Enumeral Biomedical Holdings, Inc., ACCT# 79-2997

 

____
Wire funds from my outside account according to Section 2(b) of the Subscription Agreement.

 

____
The funds for this investment are rolled over, tax deferred from __________ within the allowed 60-day window.

 

Please
check if you are a FINRA member or Affiliate of a FINRA member firm: _____

 

	 	 	 
	Investor
    Signature	 	Date

 

*       For
purposes of calculating your net worth in this form, (a) your primary residence shall not be included as an asset; (b)
indebtedness secured by your primary residence, up to the estimated fair market value of your primary residence at the time of
your purchase of the securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding
at the time of your purchase of the securities exceeds the amount outstanding sixty (60) days before such time, other than as
a result of the acquisition of your primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness
that is secured by your primary residence in excess of the estimated fair market value of your primary residence at the time of
your purchase of the securities shall be included as a liability. 

 

    	 

     

    

 

ANTI
MONEY LAUNDERING REQUIREMENTS

 

The
USA PATRIOT Act

 

The
USA PATRIOT Act is designed to detect, deter, and punish terrorists in the United States and abroad. The Act imposes new anti-money
laundering requirements on brokerage firms and financial institutions. Since April 24, 2002 all brokerage firms have been required
to have new, comprehensive anti-money laundering programs.

 

To
help you understand these efforts, we want to provide you with some information about money laundering and our steps to implement
the USA PATRIOT Act.

 

What
is money laundering?

 

Money
laundering is the process of disguising illegally obtained money so that the funds appear to come from legitimate sources or activities.
Money laundering occurs in connection with a wide variety of crimes, including illegal arms sales, drug trafficking, robbery,
fraud, racketeering, and terrorism.

 

How
big is the problem and why is it important?

 

The
use of the U.S. financial system by criminals to facilitate terrorism or other crimes could well taint our financial markets.
According to the U.S. State Department, one recent estimate puts the amount of worldwide money laundering activity at $1 trillion
a year.

 

What
are we required to do to eliminate money laundering?

 

Under
rules required by the USA PATRIOT Act, our anti-money laundering program must designate a special compliance officer, set up employee
training, conduct independent audits, and establish policies and procedures to detect and report suspicious transaction and ensure
compliance with such laws. As part of our required program, we may ask you to provide various identification documents or other
information. Until you provide the information or documents we need, we may not be able to effect any transactions for you.

 

    	 

     

    

 

ANTI-MONEY
LAUNDERING INFORMATION FORM

The
following is required in accordance with the AML provision of the USA PATRIOT ACT.

(Please
fill out and return with requested documentation.)

 

	INVESTOR
    NAME:	 
	LEGAL
    ADDRESS:	 
	 	 
	SSN#
    or TAX ID#	 
	OF
    INVESTOR:	 
	YEARLY
    INCOME:	 	 	 
	NET
    WORTH: 	 	*

 

*
For purposes of calculating your net worth in this form, (a) your primary residence shall not be included as an asset;
(b) indebtedness secured by your primary residence, up to the estimated fair market value of your primary residence at the time
of your purchase of the securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding
at the time of your purchase of the securities exceeds the amount outstanding sixty (60) days before such time, other than as
a result of the acquisition of your primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness
that is secured by your primary residence in excess of the estimated fair market value of your primary residence at the time of
your purchase of the securities shall be included as a liability. 

 

	INVESTMENT
                                         OBJECTIVE(S) (FOR ALL INVESTORS):  	  

 

	ADDRESS
    OF BUSINESS OR OF EMPLOYER:  	  

 

	  	  

 

	FOR
                                         INVESTORS WHO ARE INDIVIDUALS: AGE:  	  

 

	FOR
    INVESTORS WHO ARE INDIVIDUALS: OCCUPATION:  	  
	 	 

	FOR
    INVESTORS WHO ARE ENTITIES: TYPE OF BUSINESS:  	  

 

IDENTIFICATION
& DOCUMENTATION AND SOURCE OF FUNDS:

 

		1.	Please
                                         submit a copy of non-expired identification for the authorized signatory(ies) on the
                                         investment documents, showing name, date of birth, address and signature. The address
                                         shown on the identification document MUST match the Investor’s address shown on
                                         the Investor Signature Page.

 

	Current
    Driver’s License	or	Valid
    Passport	or	Identity
    Card

(Circle
one or more)

 

		2.	If
                                         the Investor is a corporation, limited liability company, trust or other type of entity,
                                         please submit the following requisite documents: (i) Certificate of Incorporation, By-Laws,
                                         Certificate of Formation, Operating Agreement, Trust or other similar documents for the
                                         type of entity; and (ii) Corporate Resolution or power of attorney or other similar document
                                         granting authority to signatory(ies) and designating that they are permitted to make
                                         the proposed investment.

 

		3.	Please
                                         advise where the funds were derived from to make the proposed investment:

 

	Investments	Savings	Proceeds
    of Sale	Other
    ____________

(Circle
one or more)

	Signature:	 	 	 	 
	Print
    Name:	 	 	 	 
	Title
    (if applicable):	 	 
	Date:	 	 	 	 

 

    	 

     

    

 

ENUMERAL
BIOMEDICAL HOLDINGS, INC.

CONFIDENTIALITY
AGREEMENT

 

_______________,
2017

 

To
facilitate the consideration and negotiation of a possible transaction (the “Transaction”) between Enumeral
Biomedical Holdings, Inc. (the “Company”) and the undersigned potential investor (“Investor”),
the Company is furnishing non-public information (the “Confidential Information”) to Investor. Investor agrees
to use the Confidential Information solely for the purpose of evaluating the Transaction. Investor shall keep the Confidential
Information confidential and shall not disclose any of the Confidential Information to any third person, except to the extent
that disclosure of the Confidential Information is made to Investor’s legal counsel and/or advisor(s) who need to know such
information for the sole purpose of assisting Investor in evaluating the Transaction. Investor hereby agrees to be responsible
for any violations hereof by Investor’s legal counsel and/or advisor(s).

 

Except
as permitted hereunder, Investor shall not disclose to any person (a) that the Confidential Information has been made available
to Investor, (b) that discussions or negotiations are taking place concerning the Transaction, (c) any terms, conditions or other
facts with respect to the Transaction, including the status thereof, or (d) the existence of this confidentiality agreement or
its terms.

 

Investor
hereby acknowledges that it is aware that the federal and state securities laws prohibit any person who has material, non-public
information about a company from purchasing or selling securities of such a company or from communicating such information to
any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such
securities. Nothing herein shall preclude disclosure of the Confidential Information or trading thereon after public disclosure
of the Confidential Information is made by the Company. This Agreement is effective as of the date this Agreement is executed
(the “Effective Date”), and the confidentiality obligations and other restrictions contained herein shall apply
to the Confidential Information until the six (6) month anniversary of the Effective Date.

 

All
Confidential Information disclosed shall be and shall remain the property of the Company, and this agreement shall not be construed
as a license or any other grant of any right whatsoever in connection with the Confidential Information. Promptly after being
so requested by the Company, Investor shall return or destroy (and certify such destruction in writing) all Confidential Information.

 

Accepted
and agreed to as of the date first written above:

 

	Investor
    (individual)

	 	Investor

	 	 	 
	Signature	 	Name
    of Entity
	 	 	 
	 	 	 
	Print
    Name	 	Signature
	 	 	 
	 	 	Title:	 
	Additional
    Signature	 	 

	 	 	 	 
	Print
    Name:	 	 	Print
    Name
	(if
    Joint Tenants or Tenants in Common)	 	 

 

    	 

     

    

 

EXHIBIT
A

 

Form
of Note

 

    	 

     

    

 

EXHIBIT
B

 

Form
of Warrant

 

    	 

     

    

 

EXHIBIT
C

 

Security
Agreement

 

    	 

     

    

 

EXHIBIT
D

 

Registration
Rights AgreementExhibit
10.3

ESCROW
AGREEMENT

Escrow
Agreement (the “Escrow Agreement”) dated as of the effective date (the “Effective Date”) set forth on
Schedule 1 hereto (“Schedule 1”) by and among the corporation identified as the “Company” on Schedule
1 hereto (the “Company”), the company identified on Schedule 1 hereto as Katalyst Securities LLC, (“Depositor
#1”), the company identified on Schedule 1 hereto as GP Nurmenkari, Inc., (“Depositor #2”) (Depositor #1 and
Depositor #2 collectively the “Depositors”) and Delaware Trust Company, as escrow agent hereunder (the “Escrow
Agent”).

 

WHEREAS,
the Company intends to offer and sell to certain investors (the “Subscribers”) and the Subscribers desire to purchase
from the Company in a private placement offering (the “Offering”), units of the Company (the “Units”)
consisting of (i) one 12% Senior Secured Convertible Promissory Note in the face amount of $1,150 (the “Note”) and
(ii) one warrant representing the right to purchase eleven thousand five hundred (11,500) shares of the Company’s common
stock, par value $0.001 per share (the “Common Stock”), exercisable for a period of five (5) years from issuance at
an exercise price of $0.10 per share. Each Note is convertible into shares of the Common Stock (the “Conversion Shares”)
at a conversion price and on the terms set forth in the Note. The Company intends to raise a minimum of gross proceeds of Five
Hundred Thousand Dollars ($500,000) (the “Minimum Offering Amount”) and a maximum of gross proceeds of Three Million
Six Hundred Thousand Dollars ($3,600,000), which includes a Six Hundred Thousand Dollar Over-Allotment Option, (the “Maximum
Offering Amount”). The offering price per Unit shall be One Thousand Dollars ($1,000.00) (the “Purchase Price”);

WHEREAS,
the Offering is being made on a reasonable best efforts basis until the Minimum Offering Amount is reached, to “accredited
investors,” as such term is defined in Rule 501 of Regulation D (“Regulation D”) as promulgated by the U.S.
Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities
Act”), in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act and
Rule 506 of Regulation D;

WHEREAS,
the Units may be offered through May 19, 2017 (the “Initial Offering Period”), which period may be extended, at the
discretion of the Company and the Placement Agents (this additional period and the Initial Offering Period shall be referred to
as the “Offering Period”);

WHEREAS,
the initial closing of the Offering (the “Initial Closing”) is conditioned on the receipt of acceptable subscriptions
by the Company and the satisfaction of other closing conditions (collectively, the “Initial Closing Conditions”);

WHEREAS,
after the Initial Closing, the Company and the Depositors may mutually agree to continue the Offering until the Maximum Offering
Amount has been reached or the end of the Offering Period, whichever is earlier, and subsequent closings (each, a “Subsequent
Closing”) may take place on an intermittent basis, as deemed practical by the Company and the Depositors, conditioned on
the receipt of acceptable subscriptions (this requirement for the receipt of acceptable subscriptions, together with certain other
conditions to closing, are collectively referred to as the “Subsequent Closing Conditions”);

    	 

     

    

WHEREAS,
the Subscribers in the Offering in connection with their intent to purchase the Securities in the Offering, shall execute and
deliver Subscription Agreements and certain related documents memorializing the Subscriber’s agreements to purchase and
the Company’s agreement to sell the Securities set forth therein at the Purchase Price;

WHEREAS, the parties hereto
desire to provide for the safekeeping of the Escrow Deposit (as defined below) until such time as the Escrow Deposit is released
by the Escrow Agent in accordance with the terms and conditions of this Agreement; and

WHEREAS,
the Escrow Agent has agreed to accept, hold, and disburse the Escrow Deposit deposited with it and the earnings thereon in accordance
with the terms of this Escrow Agreement.

NOW
THEREFORE, in consideration of the foregoing
and of the mutual covenants hereinafter set forth, the parties hereto agree as follows:

1.            Appointment.  The Company and Depositors hereby appoint the Escrow Agent as their escrow agent for the purposes
set forth herein, and the Escrow Agent hereby accepts such appointment under the terms and conditions set
forth herein.

2.            Escrow Fund.  On or before the Initial Closing, or on or before any Subsequent Closing with respect to the Securities
sold after the Initial Closing, each Subscriber shall have delivered to the Escrow Agent the full Purchase Price for the total
number of Securities subscribed for by such Subscriber by check sent to the Escrow Agent at its address set forth on Schedule
1 hereto, or by wire transfer of immediately available funds pursuant to the wire transfer instructions set forth on Schedule
2 hereto, to the account of the Escrow Agent referenced on Schedule 2 hereto. All funds received from the Subscribers in connection
with the sale of the Securities in the Offering shall be deposited with the Escrow Agent (the “Escrow Deposit”). The
Escrow Agent shall hold the Escrow Deposit and, subject to the terms and conditions hereof, shall invest and reinvest the Escrow
Deposit and the proceeds thereof (the “Escrow Fund”) as directed in Section 3 hereto.

3.            Investment of Escrow Fund.  During the term of this Escrow Agreement, the Escrow Fund shall be invested and
reinvested by the Escrow Agent in the investment indicated on Schedule 1 hereto, or such other investments as shall be
directed jointly in writing by the Company and the Depositors and as shall be acceptable to the Escrow Agent. All investment
orders involving U.S. Treasury obligations, commercial paper and other direct investments may be executed through
broker-dealers selected by the Escrow Agent. Periodic statements will be provided to the Company and the Depositors
reflecting transactions executed on behalf of the Escrow Fund. The Company and the Depositors, upon written request, will
receive a statement of transaction details upon completion of any securities transaction in the Escrow Fund without any
additional cost. The Escrow Agent shall have the right to liquidate any investments held in order to provide funds necessary
to make required payments under this Escrow Agreement. The Escrow Agent shall have no liability for any loss sustained as a
result of any investment in an investment indicated on Schedule 1 hereto, or any investment made pursuant to the instructions
of the parties hereto or as a result of any liquidation of any investment prior to its maturity or for the failure of the
parties to give the Escrow Agent instructions to invest or reinvest the Escrow Fund. The Escrow Agent may earn compensation
in the form of short-term interest (“float”) on items like uncashed distribution checks (from the date issued
until the date cashed), funds that the Escrow Agent is directed not to invest, deposits awaiting investment direction or
received too late to be invested overnight in previously directed investments.

    	2 

     

    

4.
          Disposition and Termination.  The Depositors and the Company agree to notify the Escrow Agent in writing of
any valid revocations and the Initial Closing date of the Offering. Additionally, subsequent to an Initial Closing, the
Depositors and the Company agree to notify the Escrow Agent in writing of Subsequent Closing dates, if any, and of the
termination of the Offering. Upon receipt of such written notification(s), the following procedures will take
place:

		(i)	Release
                                         of Escrow Fund upon Initial Closing. Prior to the Initial Closing, the Company and
                                         the Depositors shall deliver to the Escrow Agent joint written instructions executed
                                         by a duly authorized executive officer of each of the Company and the Depositors (“Instructions”),
                                         which Instructions shall provide the day designated as the Initial Closing date, and
                                         shall specify the time and payment instructions, including the address and tax identification
                                         number of each payee, of the Escrow Fund, including with respect to placement fees that
                                         may be disbursed to each Depositor or to any other placement agent or selected dealer
                                         with respect to the Offering. Further, the Instructions shall include an acknowledgement
                                         and agreement from the Company and Depositors that as of the Initial Closing date, the
                                         Initial Closing Conditions have been or will be fully satisfied. The Escrow Agent shall,
                                         at the time and in accordance with the payment instructions specified in the Instructions,
                                         deliver the Escrow Fund (without interest).

		(ii)	Release
                                         of Escrow Fund upon a Subsequent Closing. Prior to a Subsequent Closing, the Company
                                         and the Depositors shall deliver Instructions to the Escrow Agent, which Instructions
                                         shall provide the day designated as the Subsequent Closing date, and acknowledge and
                                         agree that as of the Subsequent Closing date the Subsequent Closing Conditions have been
                                         or will be fully satisfied and shall specify the time and payment instructions, including
                                         the address and tax identification number of each payee, of the Escrow Fund, including
                                         with respect to placement fees that may be disbursed to each Depositor or to any other
                                         placement agent or selected dealer. The Escrow Agent shall, at the time and in accordance
                                         with the payment instructions specified in the Instructions, deliver the then Escrow
                                         Fund (without interest).

    	3 

     

    

 

		(iii)	Release
                                         of Certain Escrow Funds on Termination of Offering. In the event that the Escrow
                                         Agent shall have received written notice executed by a duly authorized executive officer
                                         of each of the Company and the Depositors indicating that the Offering has been terminated
                                         prior to the Initial Closing and designating a termination date, the Escrow Agent shall
                                         (i) as soon as practicable provide a copy of such termination to the Depositors and (ii)
                                         return to each Subscriber, the Purchase Price (without interest and deduction) delivered
                                         by such Subscriber to the Escrow Agent. The Company and Depositors shall provide the
                                         Escrow Agent with time and payment instructions, including the address and tax identification
                                         number of each payee, for each Subscriber whose Purchase Price the Escrow Agent is to
                                         deliver pursuant to this Section (but in no case shall the Escrow Agent deliver such
                                         Purchase Price more than three (3) days following receipt by the Escrow Agent of such
                                         delivery instructions).

		(iv)	Return
                                         of Escrow Fund on Rejection of Subscription. In the event the Company determines
                                         it is necessary or appropriate to reject the subscription of any Subscriber for whom
                                         the Escrow Agent has received an Escrow Deposit, the Company shall deliver written notice
                                         of such determination to the Escrow Agent and the Depositors which notice shall include
                                         the time and payment instructions, including the address and tax identification number
                                         of each payee, for the return to such Subscriber of the Purchase Price delivered by such
                                         Subscriber. The Escrow Agent shall deliver such funds (without interest and deduction)
                                         pursuant to such written notice (but in no case shall the Escrow Agent deliver such Purchase
                                         Price more than three (3) days following receipt by the Escrow Agent of such delivery
                                         instructions).

		(v)	Return
of Escrow Fund on Revocation of Subscription. In the event that the Escrow Agent shall have received written notice executed
by a duly authorized executive officer of each of the Company and the Depositors indicating that any subscription has been revoked
prior to the Initial Closing, pursuant to the subscription agreement between the Company and the relevant Subscriber, the Escrow
Agent shall return to such revoking Subscriber, the Purchase Price (without interest and deduction) delivered by such Subscriber
to the Escrow Agent. The Company and the Depositors shall provide the Escrow Agent with time and payment instructions, including
the address and tax identification number of each payee, for each Subscriber whose Purchase Price the Escrow Agent is to deliver
pursuant to this Section (but in no case shall the Escrow Agent deliver such Purchase Price more than three (3) days following
receipt by the Escrow Agent of such delivery instructions).

		(vi)	Delivery
                                         Pursuant to Court Order. Notwithstanding any provision contained herein, upon receipt
                                         by the Escrow Agent of a final and non-appealable judgment, order, decree or award of
                                         a court of competent jurisdiction (a “Court Order”), the Escrow Agent shall
                                         deliver the Escrow Fund in accordance with the Court Order. Any Court Order shall be
                                         accompanied by an opinion of counsel for the party presenting the Court Order to the
                                         Escrow Agent (which opinion shall be satisfactory to the Escrow Agent) to the effect
                                         that the court issuing the Court Order has competent jurisdiction and that the Court
                                         Order is final and non-appealable.

    	4 

     

    

Upon
delivery of the Escrow Deposit by the Escrow Agent (i) to the Company following the Initial Closing, if there are to be no Subsequent
Closings, (ii) to the Company following a Subsequent Closing, or (iii) to the Subscribers upon termination of the Offering, prior
to the Initial Closing, as the case may be, and in each case notice of termination of the Offering having been delivered by the
Company and the Depositors to the Escrow Agent, this Escrow Agreement shall terminate, subject to the provisions of Section 8.

5.            Escrow
Agent.  The Escrow Agent undertakes to perform only such duties as are expressly set forth herein and no duties
shall be implied. The Escrow Agent shall have no liability under and no duty to inquire as to the provisions of any agreement
other than this Escrow Agreement. The Escrow Agent may rely upon and shall not be liable for acting or refraining from acting
upon any written notice, instruction or request furnished to it hereunder and believed by it to be genuine and to have been signed
or presented by the proper party or parties. The Escrow Agent shall be under no duty to inquire into or investigate the validity,
accuracy or content of any such document. The Escrow Agent shall have no duty to solicit any payments which may be due it or the
Escrow Fund. The Escrow Agent shall not be liable for any action taken or omitted by it in good faith except to the extent that
a court of competent jurisdiction determines that the Escrow Agent’s gross negligence or willful misconduct was the primary
cause of any loss to the Company or Depositors. The Escrow Agent may execute any of its powers and perform any of its duties hereunder
directly or through agents or attorneys (and shall be liable only for the careful selection of any such agent or attorney) and
may consult with counsel, accountants and other skilled persons to be selected and retained by it. The Escrow Agent shall not
be liable for anything done, suffered or omitted in good faith by it in accordance with the advice or opinion of any such counsel,
accountants or other skilled persons. In the event that the Escrow Agent shall be uncertain as to its duties or rights hereunder
or shall receive instructions, claims or demands from any party hereto which, in its opinion, conflict with any of the provisions
of this Escrow Agreement, it shall be entitled to refrain from taking any action and its sole obligation shall be to keep safely
all property held in escrow until it shall be directed otherwise in writing by all of the other parties hereto or by a final order
or judgment of a court of competent jurisdiction. Anything in this Escrow Agreement to the contrary notwithstanding, in no event
shall the Escrow Agent be liable for special, indirect or consequential loss or damage of any kind whatsoever (including but not
limited to lost profits), even if the Escrow Agent has been advised of the likelihood of such loss or damage and regardless of
the form of action.

6.            Succession.  The
Escrow Agent may resign and be discharged from its duties or obligations hereunder by giving ten (10) Business Days (as defined
below) advance notice in writing of such resignation to the other parties hereto specifying a date when such resignation shall
take effect. The Escrow Agent shall have the right to withhold an amount equal to any amount due and owing to the Escrow Agent,
plus any costs and expenses the Escrow Agent shall reasonably believe may be incurred by the Escrow Agent in connection with the
termination of the Escrow Agreement. Any corporation or association into which the Escrow Agent may be merged or converted or
with which it may be consolidated shall be the Escrow Agent under this Escrow Agreement without further act.

    	5 

     

    

7.            Fees.  The
Company agrees to (i) pay the Escrow Agent upon the Closing and from time to time thereafter reasonable compensation for the services
to be rendered hereunder, which unless otherwise agreed in writing shall be as described in Schedule 4 hereto, and (ii) pay or
reimburse the Escrow Agent upon request for all expenses, disbursements and advances, including reasonable attorney’s fees
and expenses, incurred or made by it in connection with the preparation, execution, performance, delivery, modification and termination
of this Escrow Agreement. The Escrow Agent is authorized to deduct such fees from the Escrow Fund at the time of the Initial Closing
without prior authorization from the Company or the Depositors. In the event that the Offering is terminated prior to the Initial
Closing, the Company agrees to pay the Escrow Agent the Review Fee and the Acceptance Fee as described in Schedule 4 hereto.

8.            Indemnity.  The
Company shall indemnify and save harmless the Escrow Agent and its directors, officers, agents and employees (the “indemnitees”)
from all loss, liability or expense (including the reasonable fees and expenses of in house or outside counsel) arising out of
or in connection with (i) the Escrow Agent’s execution and performance of this Escrow Agreement, except in the case of any
indemnitee to the extent that such loss, liability or expense is due to the gross negligence or willful misconduct of such indemnitee,
or (ii) its following any instructions or other directions from the Company and/or the Depositors, except to the extent that (x)
its following any such instruction or direction is in violation of the terms hereof or (y) such loss, liability or expense is
due to the gross negligence or willful misconduct of a Depositor, in which case such Depositor shall be the indemnifying party
hereunder. The parties hereto acknowledge that the foregoing indemnities shall survive the resignation or removal of the Escrow
Agent or the termination of this Escrow Agreement.

9.            TINs.  The
Company and the Depositors each represent that its correct TIN assigned by the Internal Revenue Service or any other taxing authority
is set forth in Schedule 1 hereto. No interest shall be payable under this Escrow Agreement. Unless otherwise indicated in writing
by the Company and the Depositors, no taxes or other withholdings are required to be made under applicable law or otherwise with
respect to any payment to be made by Escrow Agent. All documentation necessary to support a claim of exemption or reduction in
such taxes or other withholdings has been timely collected by Company and the Depositor and copies will be provided to Escrow
Agent promptly upon a request therefor. Unless otherwise agreed to in writing by Escrow Agent, all tax returns required to be
filed with the IRS and any other taxing authority as required by law with respect to payments made hereunder shall be timely filed
and prepared by Company and/or the Depositors, as applicable, including but not limited to any applicable reporting or withholding
pursuant to the Foreign Account Tax Compliance Act (“FATCA”).  The parties hereto acknowledge and agree that the
Escrow Agent shall have no responsibility for the preparation and/or filing of any tax return or any applicable FATCA reporting with
respect to the Escrow Fund.    The Escrow Agent shall withhold any taxes it deems appropriate, including but not
limited to required withholding in the absence of proper tax documentation, and shall remit such taxes to the appropriate authorities
as it determines may be required by any law or regulation in effect at the time of the distribution.

    	6 

     

    

10.        Notices.  All
communications hereunder shall be in writing and shall be deemed to be duly given and received:

		(i)	upon
                                         delivery if delivered personally or upon confirmed transmittal if by facsimile;

		(ii)	on
                                         the next Business Day (as defined herein) if sent by overnight courier; or

		(iii)	four
                                         (4) Business Days after mailing if mailed by prepaid registered mail, return receipt
                                         requested, to the appropriate notice address set forth on Schedule 1 hereto or at such
                                         other address as any party hereto may have furnished to the other parties in writing
                                         by registered mail, return receipt requested.

Notwithstanding
the above, in the case of communications delivered to the Escrow Agent pursuant to (ii) and (iii) of this Section 10, such communications
shall be deemed to have been given on the date received by the Escrow Agent. In the event that the Escrow Agent, in its sole discretion,
shall determine that an emergency exists, the Escrow Agent may use such other means of communication as the Escrow Agent deems
appropriate. “Business Day” shall mean any day other than a Saturday, Sunday or any other day on which the Escrow
Agent located at the notice address set forth on Schedule 1 hereto is authorized or required by law or executive order to remain
closed.

11.          Security
Procedures.  In the event funds transfer instructions are given (other than in writing at the time of execution
of this Escrow Agreement), whether in writing, by telecopier or otherwise, the Escrow Agent is authorized to seek confirmation
of such instructions by telephone call-back to the person or persons designated on Schedule 3 hereto, and the Escrow Agent may
rely upon the confirmation of anyone purporting to be the person or persons so designated. The persons and telephone numbers for
call-backs may be changed only in a writing actually received and acknowledged by the Escrow Agent. The Escrow Agent and the beneficiary’s
bank in any funds transfer may rely solely upon any account numbers or similar identifying numbers provided by the Company or
the Depositors to identify (i) the beneficiary, (ii) the beneficiary’s bank, or (iii) an intermediary bank. The Escrow Agent
may apply any of the escrowed funds for any payment order it executes using any such identifying number, even where its use may
result in a person other than the beneficiary being paid, or the transfer of funds to a bank other than the beneficiary’s
bank or an intermediary bank designated. The parties to this Escrow Agreement acknowledge that these security procedures are commercially
reasonable. 

    	7 

     

    

12.          Miscellaneous.  The
provisions of this Escrow Agreement may be waived, altered, amended or supplemented, in whole or in part, only by a writing signed
by all of the parties hereto. Neither this Escrow Agreement nor any right or interest hereunder may be assigned in whole or in
part by any party, except as provided in Section 6, without the prior consent of the other parties, which consent shall not be
unreasonably withheld. This Escrow Agreement shall be governed by and construed under the laws of the State of Delaware. Each
party hereto irrevocably waives any objection on the grounds of venue, forum non-conveniens or any similar grounds and irrevocably
consents to service of process by mail or in any other manner permitted by applicable law and consents to the jurisdiction of
the courts located in the State of Delaware. The parties further hereby waive any right to a trial by jury with respect to any
lawsuit or judicial proceeding arising or relating to this Escrow Agreement. No party to this Escrow Agreement is liable to any
other party for losses due to, or if it is unable to perform its obligations under the terms of this Escrow Agreement because
of, acts of God, fire, floods, strikes, equipment or transmission failure, or other causes reasonably beyond its control. This
Escrow Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 

SIGNATURE
PAGE TO FOLLOW

 

    	8 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Subscription Escrow Agreement as of the date set forth in Schedule
1.

 

	 	Delaware Trust Company
	 	as Escrow Agent

 

	 	By:	/s/ Alan R. Halpern	 
	 	Name: Alan R. Halpern
	 	Title: Vice President

 

	 	COMPANY
	 	 
	 	ENUMERAL BIOMEDICAL HOLDINGS, INC.

 

	 	By:	/s/ Kevin G. Sarney	 
	 	Name: Kevin G. Sarney
	 	Title: Vice President of Finance,
    Chief Accounting Officer and Treasurer

 

	 	DEPOSITOR ONE:
	 	 
	 	KATALYST SECURITIES LLC

 

	 	By:	/s/ Michael A. Silverman	 
	 	Name: Michael A. Silverman
	 	Title: Managing Director

 

	 	DEPOSITOR TWO:
	 	 
	 	GP NURMENKARI, INC.

 

	 	By:	/s/ Robert Fitzpatrick
	 	Name: Robert Fitzpatrick
	 	Title: Chief Compliance Officer

 

	 	By:	/s/ Jeffrey Berman	 
	 	Name: Jeffrey Berman
	 	Title: Director

 

     

    

    

 

Schedule
1

	Effective Date:	May 9, 2017
	 	 
	Name of Company:	

ENUMERAL
BIOMEDICAL HOLDINGS, INC.

	 	 
	Company Notice Address:	

200
Cambridge Park Drive, Suite 2000

	 	Cambridge,
        MA 02140

	 	 
	Facsimile:	617-945-9148
	 	 
	Company TIN:	99-0376434
	 	 
	

With
a copy to:

	Duane Morris LLP
	(which shall not constitute notice)	1540 Broadway
	 	

New
York, NY 10036

	 	Attn: Michael D. Schwamm

 

		Facsimile:	212
                                         208 4451

	Name of Depositor One:
    	 
	 	 
	Depositor One:	Katalyst Securities LLC
	 	1330
        Avenue of the Americas, 14th Floor

	 	New York, NY 10019
	 	Attn: Michael Silverman
	 	Email: mas@katalystsecurities.com
	Depositor One TIN:	23-3071873
	 	 
	With
    a copy to: 	Barbara J. Glenns, Esq.
	 (which
    shall not constitute notice)	30 Waterside Plaza, Suite 25G
	 	New York, NY 10010
	 	Email: bjglenns@barbarajglenns.com
	 	 
	Name of Depositor Two:	 
	 	 
	Depositor Two:	GP Nurmenkari, Inc.
	 	64 Wall Street, Suite 402
	 	Norwalk, CT 06850
	 	Email: apezone@gpnurmenkari.com
	Depositor Two TIN:	80-0560431
	 	 
	With
a copy to:	CKR Law, LP
	(which shall not constitute notice)	

1330
Avenue of the Americas, 14th Floor

	 	New York, NY 10019
	 	Attention: Scott E. Rapfogel, Esq.
	 	Email: srapfogel@ckrlaw.com
	 	 

     

    

    

 

	Escrow Deposit:	Up to $3,600,000.00, in
    whole or in parts

 

		Security:	Unit
                                         consisting of (i) one 12% Senior Secured Convertible Promissory Note in the face amount
                                         of $1,150 (the “Note”) and (ii) one warrant representing the right to purchase
                                         eleven thousand five hundred (11,500) shares of the Company’s common stock, par
                                         value $0.001 per share (the “Common Stock”), exercisable for a period of
                                         five (5) years from issuance, at an exercise price of $0.10 per share (the “Warrants”).
                                         

 

	Purchase Price:	$1,000.00 per Unit

 

		Investment:	

 

		☐	Goldman
                                         Sachs Financial Square Funds Prime Obligations Fund Service Shares (the “Share
                                         Class”), an institutional money market mutual fund for which the Escrow Agent serves
                                         as shareholder servicing agent and/or custodian or subcustodian. The parties hereto:
                                         (i) acknowledge Escrow Agent’s disclosure of the services Escrow Agent is providing
                                         to and the fees it receives from Goldman Sachs; (ii) consent to the Escrow Agent’s
                                         receipt of these fees in return for providing shareholder services for the Share Class;
                                         and (iii) acknowledge that the Escrow Agent has provided on or before the date hereof
                                         a Goldman Sachs Financial Square Funds Prime Obligations Fund Service Shares prospectus
                                         which discloses, among other things, the various expenses of the Share Class and the
                                         fees to be received by the Escrow Agent.

 

		☐	Such
                                         other investments as the Company, the Depositors and Escrow Agent may from time to time
                                         mutually agree upon in a writing executed and delivered by the Company and the Depositors
                                         and accepted by the Escrow Agent.

 

		☒	The
                                         funds shall not be invested.

 

	Escrow Agent notice address:
	 	Delaware
    Trust Company
	 	2711 Centerville Road
	 	One Little Falls Centre
	 	Wilmington, DE 19808
	 	Attention: Alan R. Halpern
	 	Email: trustadmin@delawaretrust.com
	 	Fax No.: 302-636-8666

 

Escrow
Agent’s compensation:     See Appended Schedule 4.

 

     

    

    

 

Schedule
2

 

Wire
Instructions

 

	 	PNC Bank
	 	300 Delaware Avenue
	 	Wilmington DE 19899
	 	ABA# 031100089
	 	SWIFT Code: PNCCUS33
	 	Account Name: Delaware
    Trust Company
	 	Account Number: 5605012373
	 	FFC: ENUMERAL BIOMEDICAL
    HOLDINGS, INC. Subscription
	 	Escrow #4; Account #
    79-2997
	 	MUST
    INCLUDE THE SUBSCRIBER’S NAME

 

     

    

    

 

Schedule
3

 

Telephone
Number(s) for Call-Backs and

Person(s)
Designated to Confirm Funds Transfer Instructions

 

	If to Company:	 
	 	 	 

	 	Name	 	Telephone Number(s)	 
	 	 	 
	1. 	Matthew A. Ebert	617-800-0610
	 	 	 
	2. 	Kevin G. Sarney	617-674-1872

	 	 	 
	If to Depositors:	 
	 	 	 

	 	Name		Telephone Number	 

 

	DEPOSITOR ONE - Katalyst Securities
    LLC	 
	 	 

	1.	Michael A. Silverman	917-696-1708
	 	 	 
	2.	Barbara J. Glenns	212-689-6153

 

	DEPOSITOR TWO- GP NURMENKARI, INC.	 
	 	 

	1.	Albert Pezone	212-447-5550

 

Telephone
call-backs may be made to the Company and the Depositors if joint instructions are required pursuant to this Escrow Agreement.

 

     

    

    

 

Schedule
4

 

REVIEW
FEE:

For
initial examination of the Escrow Agreement and all supporting documents. This is a one-time fee payable upon execution of the
agreement.

$500.00

 

ACCEPTANCE
FEE:

For
initial services associated with establishing the Escrow Account. This is a one-time fee payable upon execution of the agreement.

$500.00

 

ANNUAL
ADMINISTRATION FEE:

An
annual charge or any portion of a 12-month period thereof. This fee is payable 45 days after the opening of the Escrow Account
or prior to the final disbursement of the Escrow Fund, whichever event occurs first, and in advance of the annual anniversary
date thereafter. This charge is not prorated for the first year. There is an additional annual charge of $250.00/subaccount
opened.

 

$2,250.00
covering up to 100 deposits. There will be an additional administration fee of $750.00 for each block of 50 deposits over the
initial 100 deposits.

 

TRANSACTION
FEES: 

Wire
transfer of fund: $35.00/domestic wire initiated; $50.00/international wire initiated

Checks
Cut: $10.00/check cut

Securities
Purchase (Buy and Sell): $50.00/transaction

Returned
Check: $30.00/returned item

 

Out-of-pocket
expenses, fees and disbursements and services of an unanticipated or unexpected nature are not included in the above schedule.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]